Skip to main content
SpringerLink
Log in

Lymphokines and Cytokines

  • Chapter
Principles of Cancer Biotherapy

Abstract

The study of lymphokines began in the mid 1960s, after the simultaneous discovery by David (1966) and Bloom and Bennett (1966) that in vitro activation of lymphocytes leads to the production of factors that inhibit the migration of macrophages [468]. Subsequently, DuMonde et al. (1969) coined the term lymphokines to refer to factors that modulate the growth or mobility of a variety of leukocytes [167]. Hundreds of communication molecules have now been described, which are produced by both lymphocytic and nonlymphocytic cells. Nonlymphocytic cells involved in this process include normal macrophages, fibroblasts, mast cells, and eosinophils. It was therefore proposed by Cohen and co-workers in 1977 that this entire class of mediators be termed cytokines, in recognition of the contribution from nonlymphocytic components. It is now recognized that cytokines may function in a wide range of activities, including regulation of immunological and inflammatory processes, which not only regulate normal cell growth and differentiation but also participate in repair mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abehsira-Amar O, Gilbert M, Joliy M, et al. IL-4 plays a dominant role in the differential development of Th0 into Thl and Th2 cells. J Immunol 1992; 148: 3820–9.

    PubMed  CAS  Google Scholar 

  2. Abrams J, Rayner A, Wiernik P, Parkinson D. High dose interleukin-2 without lymphokine activated killer cells: inactive in advanced renal cell cancer (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1989; 30: A1507.

    Google Scholar 

  3. Adams DO, Hall T, Steplewski Z, et al. Tumor undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contained increased numbers of macrophages activated for a distinctive form of antibody dependent cytostasis. Proc Natl Acad Sci (USA) 1984; 81: 3506.

    CAS  Google Scholar 

  4. Adler A, Albo V, Blatt J, et al. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission. Blood 1989; 74: 1690.

    PubMed  CAS  Google Scholar 

  5. Adler A, Chervenick PA, Whiteside TL, et al. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988; 71: 709.

    PubMed  CAS  Google Scholar 

  6. Aggarwal BB, Henzel WL, Moffat B, et al. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem 1985; 260: 2334–2344.

    PubMed  CAS  Google Scholar 

  7. Akahoski T, Oppenheim J J, and Matsushima K. Induction of high affinity interleukin 1 receptor on human peripheral blood lymphocytes by glucocorticosteroid hormones. J Exp Med 1988; 167: 924–936.

    Google Scholar 

  8. Akashi K. Role of interleukin 4 in the negative regulation of leukemia cell growth. Leukemia and Lymphoma. 1993; 9:205–209.

    PubMed  CAS  Google Scholar 

  9. AlJabaari b, Ladyman HM, Larche M, et al. Elevated expression of interleukin 4 receptor in carcinoma, a target for immunotherapy? British J Cancer 1989; 59: 910–914.

    Google Scholar 

  10. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin 7 enhances cytotoxic T lymphocyte generation and induces lymphokine activated killer cells from peripheral blood. J Exp Med 1990; 172: 577–587.

    PubMed  CAS  Google Scholar 

  11. Alderson MR, Tough TW, Ziegler SF, Grabstein KW. Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991; 173:923–930.

    PubMed  CAS  Google Scholar 

  12. Allegretta M, Atkins MB, Dempsey RA, et al. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J Clin Immunol 1986; 6:481.

    PubMed  CAS  Google Scholar 

  13. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54:6022–6026.

    PubMed  CAS  Google Scholar 

  14. Allison MK, Jones SE, McGuffey P. Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic, leukemia, and selected solid tumors. J Clin Oncol 1989; 7: 75–80.

    PubMed  CAS  Google Scholar 

  15. Ambrus JL and Fauci AS. Human B cell lymphoma cell line producing B cell growth factor. J Clin Invest 1985; 75:732–730.

    PubMed  CAS  Google Scholar 

  16. Ambrus JL, Jurgenson CH, Broom EJ, Fauci AS. Purification to homology of a high molecular weight human B cell growth factor. J Exp Med 1985; 162: 1319–1335.

    PubMed  CAS  Google Scholar 

  17. Ambrus JL Chesky L, Stephany D, et al. Functional studies examining the subpopulation of human B lymphocytes responding to high molecular weight B cell growth factor. J Immunol 1990; 145: 3949–3955.

    PubMed  CAS  Google Scholar 

  18. Ambrus JL, Pippin J, Joseph A, et al. Identification of a cDNA for a human high molecular weight B cell growth factor. Proc Nat Acad Sci USA 1993; 90: 6330–6334.

    PubMed  CAS  Google Scholar 

  19. Anderson DM, Lyman S, Baird A, et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990;63:235–243.

    PubMed  CAS  Google Scholar 

  20. Andrews JVR, Schoof DD, Bertagnolli MM, et al. Immunomodulatory effects of Interleukin 12 on human tumor infiltrating lymphocytes. J Immunotherapy 1993; 14: 1–10.

    CAS  Google Scholar 

  21. Aoki T, Kikuchi H, Miyatake S-I, et al. Interleukin 5 enhances interleukin 2 mediated lymphokine activated killer activity. J Exp Med 1989; 23: 163–177.

    Google Scholar 

  22. Aoki T, Tashiro K, Miyatake S, et al. Expression of murine IL-7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 1992; 89: 3850–3894.

    PubMed  CAS  Google Scholar 

  23. Appasamy PM, Kenniston TW, Weng YH, et al. Interleukin 7 induced expression of specific T cell receptor gamma variable region genes in murine fetal liver cultures. J Exp Med 1993; 178: 2201–2206.

    PubMed  CAS  Google Scholar 

  24. Argetsinger LS, Campbell GS, Yang X, et al. Identification of JAK2 as a growth hormone receptor associated tyrosine kinase. Cell 1994; 74: 237–244.

    Google Scholar 

  25. Ariizumi K, Meng Y, Bergstresser PR, Takashima A. INFy- Dependent IL-7 gene regulation in keratinocytes. J Immunol 1995; 154: 6031–6039.

    PubMed  CAS  Google Scholar 

  26. Armitage RJ, Namen AE, Sassenfeld HM, Grabstein KH. Regulation of human T cell proliferation by IL-7. J Immunol 1989; 144: 938–941.

    Google Scholar 

  27. Armitage RJ, Namen AE, Sassenfeld HM, Grabstein KH. Regulation of T cell proliferation by IL-7. J Immunol 1990; 144: 938.

    PubMed  CAS  Google Scholar 

  28. Armitage RJ, Macduff BM, Ziegler SF Grabstein KH. Multiple cytokine secretion by IL-7 stimulated human T cells. Cytokine 1992; 4:461–4691992.

    PubMed  CAS  Google Scholar 

  29. Armitage RJ, Zeigler SF, Friend DJ, et al. Identification of a novel low affinity receptor for human interleukin-7. Blood 1992; 7: 1738.

    Google Scholar 

  30. Armitage RJ, MacDuff BM, Eisenman J, et al. IL-15 has stimulatory activity in the induction of B cell proliferation and differentiation. J Immunol 1995; 154:483–490.

    PubMed  CAS  Google Scholar 

  31. Aronson FR, Libby P, Brandon EP, et al. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol 1988; 141: 158.

    PubMed  CAS  Google Scholar 

  32. Atkins MB, Gould JA, Allegretta M, et al. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 1986; 4: 1380.

    PubMed  CAS  Google Scholar 

  33. Atkins MB, Vachino G, Tilg HJ, et al. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin One 1992; 10: 1802–1809.

    CAS  Google Scholar 

  34. Atzpodien J, Korfer A, Evers P, et al. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study. Mol Biother 1990; 2: 18–26.

    PubMed  CAS  Google Scholar 

  35. Atzpodien J, Korfer A, Franks CR, et al. Home therapy with recombinant interleukin-2 and interferon-a2b in advanced human malignancies. Lancet 1990; 335: 1509–1512.

    PubMed  CAS  Google Scholar 

  36. Auget M, Dembie Z, Merlin G. Molecular cloning and expression of the human interferon y receptor. Cell 1988; 55:273–280.

    Google Scholar 

  37. Avanzi GC, Brizzi MF, Gianotti J, et al. M-07e human leukemic factor dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3 .J Cell Physiol 1990; 145:458–464.

    PubMed  CAS  Google Scholar 

  38. Aversa G, Punnonen J, Cocks BG, et al. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13 induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. J Exp Med 1993; 178: 2213.

    PubMed  CAS  Google Scholar 

  39. Bacon KB, Westwick J, Camp RDR. Potent and specific inhibition of IL8, ILl a and p induced in vitro human lymphocyte migration by calcium channel antagonists. Biochem Biophys Res Commun 1989; 165: 349.

    PubMed  CAS  Google Scholar 

  40. Baggiolini M, Kernan P. Neutrophil activation: control of shape change exocytosis and respiratory burst. News Physiol Sci 1992; 7:215.

    CAS  Google Scholar 

  41. Balsari A, Marolda R, Gambacorti-Passerini C, et al. Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study. Cancer Immunol Immunother 1986; 21: 148.

    CAS  Google Scholar 

  42. Bamford RN, Grant AJ, Burton JD, et al. The interleukin (IL) 2 beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T that stimulates T cell proliferation and the induction of lymphokine activated killer cells. Proc Nat Acad Sci USA 1994; 91:4940–4944.

    PubMed  CAS  Google Scholar 

  43. Barba D, Saris SC, Holder C, et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989; 70: 175.

    PubMed  CAS  Google Scholar 

  44. Barth RJ, Mule JJ, Speiss PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor infiltrating lymphocytes. J Exp Med 1991; 173: 647–658.

    PubMed  CAS  Google Scholar 

  45. Bazan JF. Emerging families of cytokines and receptors. Curr Biol 1993; 5:459–462.

    Google Scholar 

  46. Beckman MP, Cosman D, Fanslow W, et al. The interleukin 4 receptor: structure function and signal transduction. Chem Immunol 1992; 51: 107.

    Google Scholar 

  47. Bedard M, Mclure CD, Schiller NL, et al. Release of interleukin 8, interleukin 6, and colony stimulating factors by upper airway epithelial cells: implications for cystic fibrosis. Am J Respir Cell Mol Biol 1993; 9:455.

    PubMed  CAS  Google Scholar 

  48. Bellone G, Trinchieri G. Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 1994; 153: 930–937.

    PubMed  CAS  Google Scholar 

  49. Ben-Sasson SZ, LeGros G, Conrad DH, et al. IL-4 production by T cells from naive donors. J Immunol 1990; 145: 1127–1136.

    PubMed  CAS  Google Scholar 

  50. Benjamin D, Sharma V, Knobloch TJ, et al. B cell IL7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J Immunol 1994; 152:4749–4757.

    PubMed  CAS  Google Scholar 

  51. Berdel WE, Danhauser Riedl S, Steinhauser G, Winton EF. Various human hematopoietic growth factors (interleukin 3, GM CSF, G CSF) stimulate clonal growth of non-hematopoietic tumor cells. Blood 1989; 73: 80–83.

    PubMed  CAS  Google Scholar 

  52. Bertagnolli M and Herrmann S. IL7 supports the generation of cytotoxic T lymphocytes from thymocytes. J Immunol 1990; 145: 1706–1712.

    PubMed  CAS  Google Scholar 

  53. Bertoglio S, Melioli G, Baldini E, et al. Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer. Acta Med Austriaca 1989; 16: 81–83.

    PubMed  CAS  Google Scholar 

  54. Besedovsky H, delRey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986; 233: 652–654.

    PubMed  CAS  Google Scholar 

  55. Beutler B, Mahoney J, LeTrang N, et al. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 2264.7 cells. J Exp Med 1985; 161:984.

    PubMed  CAS  Google Scholar 

  56. Beutler B, Milsark I, Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869.

    PubMed  CAS  Google Scholar 

  57. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage secreted factor cachectin. Nature 1985; 316: 552–554.

    PubMed  CAS  Google Scholar 

  58. Beutler B, ed. Tumor necrosis factors: the molecules and their emerging role in medicine. Raven Press New York, 1992 1–590.

    Google Scholar 

  59. Beutler B, Tkacenko V, Milasark I, et al. Control of cachechtin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977–979.

    PubMed  CAS  Google Scholar 

  60. Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985; 135: 3969–3971.

    PubMed  CAS  Google Scholar 

  61. Blanchereau J, Briere F, Galizzi JP, et al. Human Interleukin 4. J Lipid Mediators Cell Signaling 1994; 9: 43–53.

    Google Scholar 

  62. Blankenstein T, Qin Z, Uberla K, et al. Tumor suppression after cell targeted tumor necrosis factor a gene transfer. J Exp Med 1991; 173: 1047–1052.

    PubMed  CAS  Google Scholar 

  63. Blin N, Stafford DW. Isolation of high molecular weight DNA. Nucleic Acid Res 1976; 3: 2303.

    PubMed  CAS  Google Scholar 

  64. Bogdan C, Vodovotz Y, Nathan CF. Macrophage inactivation by interleukin 10. J Exp Med 1991; 174: 1549.

    PubMed  CAS  Google Scholar 

  65. Boldt DH, Mills BJ, Gemlo BT, et al. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in human. Cancer Res 1988; 48:4409.

    PubMed  CAS  Google Scholar 

  66. Bonnema J, Rivlin KA, Ting AT, et al. Cytokine enhanced natural killer cells mediated cytotoxicity. Positive modulatory effects of IL2 and ILl2 on stimulus -dependent granule exocytosis. J Immunol 1994; 152:2098–2104.

    PubMed  CAS  Google Scholar 

  67. Boulay JL, Paul WE. The interleukin-4 related lymphokines and their binding to hematopoietic receptors. J Biol Chem 1992; 267: 20525–20528.

    PubMed  CAS  Google Scholar 

  68. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized and released by human mast cells. J Exp Med 1992; 176: 1381.

    PubMed  CAS  Google Scholar 

  69. Bradley EC, Louis AC, Paradise CM, et al. Antitumor response in patients with metastatic renal cell carcinoma is dependent upon regimen intensity (meeting abstract). Proc Am Soc Clin Oncol 1989; 8: A519.

    Google Scholar 

  70. Braun RK, Francini M, Erard F, et al. Human peripheral blood eosinophils produce and release interleukin 8 on stimulation with calcium ionophore. Eur J Immunol 1993; 23: 956.

    PubMed  CAS  Google Scholar 

  71. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effects of TNF a antibodies on synovial cell interleukin 1 production in rheumatoid arthritis. Lancet 1989; 11: 244.

    Google Scholar 

  72. Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage colony stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992; 90: 1414.

    PubMed  CAS  Google Scholar 

  73. Brooks B, Rees RC. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity. Clin Exp Immunol 1988; 74: 162.

    PubMed  CAS  Google Scholar 

  74. Brown MA, Pierce JH, Watson CJ, et al. B cell stimulatory factor-1/Interleukin-4 is expressed by normal and transformed mast cells. Cell 1987; 50: 809–818.

    PubMed  CAS  Google Scholar 

  75. Browning JL, Mattaliano RJ, Pinchang CE, et al. Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers. Anal Biochem 1986; 155: 123.

    PubMed  CAS  Google Scholar 

  76. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 178: 1223–30.

    PubMed  CAS  Google Scholar 

  77. Bukowski RM, Murthy S, Sergi J, et al. Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-a2a: clinical effects. J Biologic Resp Mod 1990; 9: 538–545.

    CAS  Google Scholar 

  78. Burton JD, Bamford RM, Peters C, et al. A lymphokine provisionally designated interleukin T and produced by a human adult T cell leukemia line stimulates T cell proliferation and the induction of lymphokine activated killer cells. Proc Nat Acad Sci USA 1994; 91:4935–4939.

    PubMed  CAS  Google Scholar 

  79. Butler J, Sleij fer DT, van der Graaf WTA, et al. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol 1993; 20: 16–21.

    Google Scholar 

  80. Cameron RB, Mcintosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alphainterferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48: 5810.

    PubMed  CAS  Google Scholar 

  81. Cantrell MA, Anderson D, Cerretti DP, et al. Cloning sequence and expression of human granulocyte-macrophage colony stimulating factor. Proc Natl Acad (USA) 1985; 82: 6250.

    CAS  Google Scholar 

  82. Carson WE, Giri JG, Lindenmann MJ, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor J Exp Med 1994; 180: 1395.

    PubMed  CAS  Google Scholar 

  83. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin induced serum factor that causes necrosis of tumors Proc Nat Acad Sci USA 1975; 25: 3666–3670.

    Google Scholar 

  84. Carveth HJ, Bohnsack JF, Mclntyre TM, et al. Neutrophil activating factor (NAF) induces polymorphonuclear leukocyte adherence to endothelial cells and to subendothelial matrix proteins. Biochem Biophys Res Commun 1989; 162: 387.

    PubMed  CAS  Google Scholar 

  85. Cascinelli N, Belli F, Marchini S, et al. A phase II study of the administration of recombinant interleukin 2 plus lymphokine activated killer cells in stage IV melanoma patients. Tumori 1989; 75: 233.

    PubMed  CAS  Google Scholar 

  86. Casey LS, Lichtman AH, Boothby M. IL-4 induced IL-2 receptor p75 beta chain gene expression and IL-2 dependent proliferation in mouse T lymphocytes. J Immunol 1992; 148:3418–26.

    PubMed  CAS  Google Scholar 

  87. Cassatella M, Bazzoni F, Ceska M, et al. IL-8 production by human polymorphonuclear leukocytes: the chemoattractant formylmethionyl leucylphenylalanine induces the pathway. J Immunol 1992; 148: 3216.

    PubMed  CAS  Google Scholar 

  88. Caux C, Dezutter-Dambuyant D, Schmitt D, Banchereau J. GM-CSF and TNF cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360,258.

    PubMed  CAS  Google Scholar 

  89. Cesano A, Visonneau S, Clark SC, Santoli D. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J Immunol 1993; 151: 2943.

    PubMed  CAS  Google Scholar 

  90. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon y production by natural killer cell stimulatory factor: characterization of responding cells and synergy with other inducers. J Exp Med 1991; 173: 869–879.

    PubMed  CAS  Google Scholar 

  91. Chazen GD, Pereira GMB, LeGross G, et al. Interleukin 7 is a T cell growth factor. Proc Nat Acad Sci USA 1989; 86: 5923–5927.

    PubMed  CAS  Google Scholar 

  92. Chebath J, Benech P, Hovanessian A, et al. Four different forma of interferon induced 2’-5’ oligo(A)synthetase identified by immunoblotting in human cells. J Biol Chem 1987;262:3852–3857.

    PubMed  CAS  Google Scholar 

  93. Cheever MA, Thompson JA, Kern DE, Greenberg PD. Interleukin 2 administration in vivo: influence of IL-2 route and timing on T cell growth. J Immunol 1985; 134: 3895.

    PubMed  CAS  Google Scholar 

  94. Chemini J, Starr S, Frank I. Natural killer cell stimulatory factor (NKSF) increases the cytotoxic activity of NK cells from both healthy donors and HIV-infected patients. J Exp Med 1992; 175: 789–788.

    Google Scholar 

  95. Chen WF, Zlotnik A. IL10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528.

    PubMed  CAS  Google Scholar 

  96. Chien Y, Gascoigne N, Kavaler J, et al. Somatic recombination in a murine T-cell-receptor gene. Nature 1984; 309: 322.

    PubMed  CAS  Google Scholar 

  97. Chilton PM, Fernandez-Botran R. Production of soluble IL-4 receptors by murine spleen cells is regulated by activation and IL-4. J Immunol 151: 5907–5917.

    Google Scholar 

  98. Chiu C-P, Moulds C, Coffinan RL, et al. Multiple biological activities are expressed by a mouse interleukin 6 cDNA clone isolated from bone marrow stromal cells. Proc Nat Acad Sci USA 1988; 85: 7099–7103.

    PubMed  CAS  Google Scholar 

  99. Chizzonite R, Truitt T, Kilian PL, et al. Two high affinity interleukin 1 receptors represent separate gene products. Proc Nat Acad Sci USA 1989; 86: 8029.

    PubMed  CAS  Google Scholar 

  100. Chizzonite R, Truitt T, Desai BB, et al. IL-12 Receptor. I. Characterization of the receptor on phytohemagglutininactivated human lymphoblasts. J Immunol 1992; 148: 3117–3124.

    PubMed  CAS  Google Scholar 

  101. Chua AO, Chizzonite R, Desai BB, et al. Expression cloning of a human IL-12 receptor component. J Immunol 1994; 153:128–136.

    PubMed  CAS  Google Scholar 

  102. Claasen JL, Levine AD, Buckley RH. Recombinant human IL-4 induces IgE and IgG synthesis by normal and atopic donor mononuclear cells. J Immunol 1991; 144: 123–130.

    Google Scholar 

  103. Clamin H. Mast cells, T-cells, and abnormal fibrosis. Immunol Today 1985; 6:192.

    Google Scholar 

  104. Clark-Lewis I, Schrader JW. P-cell stimulating factor: biochemical characterization of a new T-cell-derived factor. J Immunol 1981; 127: 1941.

    PubMed  CAS  Google Scholar 

  105. Clark-Lewis I, Kent SBH, Schrader JW. Purification to apparent homogeneity of a factor stimulating the growth of multiple lineages of hemopoietic cells. J Biol Chem 1984; 259: 7488.

    PubMed  CAS  Google Scholar 

  106. Clerici M, Lucey DR, Berzofsky JA, et al. Restoration of HIV-mediated immune responses by interleukin 12 in vitro. Science 1993; 262: 1721–1724.

    PubMed  CAS  Google Scholar 

  107. Coffman RL, Bond MW, Carty J, et al. B cell stimulatory factor 1 enhances the IgE response of lipopolysaccharideactivated B cells. J Immunol 1986; 136:4538–4541.

    PubMed  CAS  Google Scholar 

  108. Cohen PA, Kim H, Fowler DH, et al. Use of Interleukin-7, Interleukin-2 and Interferon-y to propagate CD4+ T cells in culture with maintained Antigen Specificity. J Immunother 1993; 14:242–252.

    CAS  Google Scholar 

  109. Contractor V, Pippin J, Russell J, et al. Identification of cDNA and genomic localization for ILl4. FASEBJ 1994; 8: A506.

    Google Scholar 

  110. Copeland NG, Gilgert DJ, Cho BC, et al. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 1990; 63: 175–183.

    PubMed  CAS  Google Scholar 

  111. Cortesina G, DeStefani A, Gioverelli M, et al. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 1988; 62:2482.

    PubMed  CAS  Google Scholar 

  112. Costello R, Brailly H, Mallet F, et al. Interleukin-7 is a potent costimulus of the adhesion pathway involving CD2 and CD28 molecules. Immunology 1993; 80:451–457.

    PubMed  CAS  Google Scholar 

  113. Costino G, Soprana E, Thienes CP, et al. ILl3 down regulates CD 14 expression and TNFa secretion in normal human monocytes. J Immunol 1995; 155: 3145–3151.

    Google Scholar 

  114. Cotran RS, Pober JS, Gimbrone MA Jr, et al. Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1987; 139:1883.

    Google Scholar 

  115. Crawford R, Finboom D, Ohara J, et al. B cell stimulatory factor 1 (Interleukin 4) activates macrophages for increased tumoricidal activity and expression of la antigens. J Immunol 1981; 139: 135.

    Google Scholar 

  116. Creekmore SP, Harris JE, Ellis TM, et al. A Phase I clinical trial of recombinant interleukin-2 by periodic 24- hour intravenous infusions. J Clin Oncol 1989; 7: 276–284.

    PubMed  CAS  Google Scholar 

  117. Croghan M, Hersh EM, Taylor C, et al. Phase I-II study of low dose Cytoxan and recombinant interleukin 2 (IL-2) for the treatment of disseminated carcinoma (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A699.

    Google Scholar 

  118. Crown J, Jakubowski A, Kemeny N, et al. A phase I trial of recombinant human interleukin-1(3 alone and in combination with myelosuppressive doses of 4-fluorouracil in patients with gastrointestinal cancer. Blood 1991; 78: 1420–1427.

    PubMed  CAS  Google Scholar 

  119. Cuttitta F, Mulshine J, Moody TW, et al. Bombesin-like peptide can function as autocrine growth factors in human small cell lung cancer. Nature 1985; 316: 823.

    PubMed  CAS  Google Scholar 

  120. Dadi KH and Roifman CM. Interleukin 7 receptor mediates the activation of phosphatidyl-3 inositol kinase in human B-cell precursors. Biochem Biophys Res Commun 1993;192:450–64.

    Google Scholar 

  121. Dadi KH and Roifman CM. Activation of phosphatidylinositol- 3 kinase by ligation of the interleukin 7 receptor on human thymocytes. J Clin Invest 1993; 92: 1559–63.

    PubMed  CAS  Google Scholar 

  122. Dai CH, Krantz SB, Zsebo KM. Human burst forming units erythroid need direct interaction with stem cell factor for further development Blood 1991; 78: 2493–2497.

    PubMed  CAS  Google Scholar 

  123. Dalloul A, Laroche L, Bagot M, et al. Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest 1992; 90,1054–1060.

    PubMed  CAS  Google Scholar 

  124. Damle NK, Doyle LV, Bender JR, Bradley EC. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 1987; 138: 1779.

    PubMed  CAS  Google Scholar 

  125. Damle NK, Doyle LV Distinct regulatory effects of IL-4 and TNF- during CD3-independent initiation human T cell activation. Lymphokine Res 1989; 8: 85.

    PubMed  CAS  Google Scholar 

  126. D’Andrea A, Aste-Amezaga M, Valiante NM, et al. Interleukin-10 inhibits human lymphocyte INF- production by suppressing natural killer cell stimulatory factor/interleukin 12 synthesis in accessory cells. J Exp Med 1993; 178: 1041–1048.

    PubMed  Google Scholar 

  127. D’ Andrea A, Rangaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387–1398.

    PubMed  Google Scholar 

  128. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation response to IFNs and other extracellular signalling proteins. Science 1994; 264: 1415–1421.

    PubMed  CAS  Google Scholar 

  129. Dayer JM, deRochemonteix B, Burrus B, et al. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by synovial cells. J Clin Invest 1986; 77: 645–648.

    PubMed  CAS  Google Scholar 

  130. Dedhar D. Gaboury L, Galloway P, Evans C. Human granulocyte macrophage colony stimulating factor is a growth factor for a variety of cell types of non-hematopoietic origin. Proc Nat Acad Sci USA 1988; 83: 9253–9257.

    Google Scholar 

  131. Defrance T, Fluckinger AC, Rossi JF, et al. Antiproliferative effects of Interleukin-4 on freshly isolated nonhodgkin malignant B cell lymphoma cells. Blood 1992; 79:990–996.

    PubMed  CAS  Google Scholar 

  132. DeLarco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci (USA) 1978; 75:4001.

    Google Scholar 

  133. DelPozo V, DeAndreas B, Martin E, et al. Eosinophil as antigen presenting cells: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing. Eur J Immunol 1992; 22: 1919.

    PubMed  Google Scholar 

  134. DelPrete G, Maggi E, Parronchi P, et al. IL4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988; 140: 4193–4198.

    PubMed  Google Scholar 

  135. Dennig D, O’Reilly RJ. L7 induces surface expression of B7/BB1 on Pre-B cells and an associated increase in their costimulatory effects on T cell proliferation. Cellular Immunol 1994; 153:227–238.

    CAS  Google Scholar 

  136. Dentener MA, Bazil V, VonAsmuth EJU, et al. Involvement of CD 14 in lipopolysaccharide induced tumor necrosis factor a, IL6, and IL8 release by human monocytes and alveolar macrophages. J Immunol 1993; 150: 2885.

    PubMed  CAS  Google Scholar 

  137. Desai BB, Quinn PM, Wolitzky AS, et al. IL-12 Receptor II. Distribution and expression of receptor expression. J Immunol 1992; 148: 3125–3132.

    PubMed  CAS  Google Scholar 

  138. Desai BB, Truit T, Honasoge S, et al. Expression of functional IL-12R on a human IL2-dependent cell line. J Immunol 1993; 150:207A.

    Google Scholar 

  139. Desreumauz P, Janin A, Colombel JF, et al. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med 1992; 175: 293.

    Google Scholar 

  140. DeVita VT Jr, Hellman S, Rosenberg S A, eds. In: Biologic Therapy of Cancer, Second Edition. Philadelphia, J.B. Lippincott Company, 1995: pp. 235–249.

    Google Scholar 

  141. DeWaal Malefyt R, Figdor C, Huijbens R, et al. Effects of ILl3 on phenotype, cytokine production and cytotoxic function of human monocytes. J Immunol 1993; 151: 6370–6381.

    Google Scholar 

  142. DeWaal Malefyt R, Haansen J, et al. IL-10 and viral IL10 strongly reduce antigen specific T cell proliferation by diminishing the antigen presenting capacity of monocytes vial downregulation of class II MHC expression. J Exp Med 1991a; 174:915.

    Google Scholar 

  143. DeWaal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 by monocytes. J Exp Med 1991b; 174: 1209.

    Google Scholar 

  144. Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T. Purification and partial sequence of human osteoclast activating factor: identity with interleukin-1 beta. J Immunol 1985; 135: 2562–2568.

    PubMed  CAS  Google Scholar 

  145. Dillman RO, Barth N, Oldham RK, et al. Continuous interleukin-2 and lymphokine-activated killer cells in advanced cancer (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A730.

    Google Scholar 

  146. Dillman RO, Oldham RK, Barth NM, et al. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: A National Biotherapy Study Group Trial. J Natl Cancer Inst 1990; 82(16) 1345–1349.

    PubMed  CAS  Google Scholar 

  147. Dillman RO, Oldham RK, Tauer KW, et al. Continuous Interleukin-2 and lymphokine activated killer cells for advanced cancer: An NBSG trial. J Clin Oncol 1991; 9: 1233–1240.

    PubMed  CAS  Google Scholar 

  148. Dillman R, Church C, Oldham RK, et al. Inpatient continuous infusion interleukin-2 in 788 cancer patients: the NBSG experience. Cancer 1993; 71: 2358–2370.

    PubMed  CAS  Google Scholar 

  149. Dillman RO. The clinical experience with Interleukin-2 in cancer therapy. Cancer Biotherapy 1994; 9(3) 183–210.

    PubMed  CAS  Google Scholar 

  150. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2: 108–115.

    PubMed  CAS  Google Scholar 

  151. Dinarello CA, Goldin NP, Wolf SM. Demonstration and characterization of two distinct human leukocyte pyrogens. J Exp Med 1974; 139: 1369.

    PubMed  CAS  Google Scholar 

  152. Dinarello CR, Cannon JG, Wolff SM, et al. Tumor necrosis factor (Cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433.

    PubMed  CAS  Google Scholar 

  153. Dinarello CA. Blocking Interleukin 1 receptors. Int J Clin Lab Res 1994; 24:61–79.

    PubMed  CAS  Google Scholar 

  154. Ditonno P, Tso CL, Sakata T, et al. Regulatory effects of interleukin-7 on renal tumor infiltrating lymphocytes. Urological Res 1992; 20: 205–210.

    CAS  Google Scholar 

  155. Doherty TM, Kastelein R, Menon S, et al. Modulation of murine macrophages function by IL-13. J Immunol 1993; 151:7151.

    PubMed  CAS  Google Scholar 

  156. Dokter WH, Sierdsema SJ, Esselink MT, et al. IL7 enhances expression of IL-3 and granulocyte-macrophage- CSF mRNA in activated human T cells by post transcriptional mechanisms. J Immunol 1993; 150: 2584–90.

    PubMed  CAS  Google Scholar 

  157. Dokter WH, Sierdsema SJ, Esselink MT, et al. Interleukin 4 mRNA and protein in activated human T cells are enhanced by Interleukin 7. Exp Hematology 1994; 22: 74–79.

    CAS  Google Scholar 

  158. Domzig W, Stadler BM, Herberman RB. Interleukin 2 dependence of human natural killer (LAK) cell activity. J Immunol 1983; 130: 1970.

    PubMed  CAS  Google Scholar 

  159. Donohoe RE, Yang YC, Clark SC. Human P40 T cell growth factor (interleukin 9) supports erythroid colony formation. Blood 1990; 75: 2271–2275.

    Google Scholar 

  160. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol 1983; 130: 2203.

    PubMed  CAS  Google Scholar 

  161. Donohue JH, Rosenstein M, Chang AE, et al. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocyte lines to cure a disseminated syngeneic lymphoma. J Immunol 1984;132: 2123.

    PubMed  CAS  Google Scholar 

  162. Doolittle RF, Hunmkapillar MW, Hood LE, et al. Simian sarcoma virus oncogene, Vsis, is derived from the gene encoding a platelet-derived growth factor. Science 1983; 221:275.

    PubMed  CAS  Google Scholar 

  163. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and V-erb B oncogene protein sequences. Nature 1984; 307: 521.

    PubMed  CAS  Google Scholar 

  164. Doyle MV, Lee MT, Fong S. Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2. J Biol Response Modif 1985; 4: 96.

    CAS  Google Scholar 

  165. Dripps DJ, et al. J Biol Chem 1991;266: 10331.

    PubMed  CAS  Google Scholar 

  166. Dubucquoi S, Desreumaux P, Janin A, et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin -dependent secretion. J Exp Med 1994; 179: 703.

    PubMed  CAS  Google Scholar 

  167. DuMonde DC, Wolstencraft RA, Panavei GS, et al. Nature 1969; 224:38.

    Google Scholar 

  168. Dupere S, Obiri N, Lackey A, et al. Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro. J Biol Modif 1990 9(2) 140–148.

    CAS  Google Scholar 

  169. Dutcher JP, Creekmore S, Weiss GR, et al. A Phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7:477.

    PubMed  CAS  Google Scholar 

  170. Eastgate JA, Wood N, DiGiovine FS, et al. Correlation of plasma ILl levels with disease activity in rheumatoid arthritis. EMBO 1991; 10:4025.

    Google Scholar 

  171. Eberlein TJ, Schoof DD, Jung S, et al. A new regimen of interleukin 2 and lymphokine-activated killer cells. Arch Intern Med 1988; 148:2571.

    PubMed  CAS  Google Scholar 

  172. Economou JS, McBride WH, Essner R, et al. Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo. Immunology 1989; 67: 514.

    PubMed  CAS  Google Scholar 

  173. Eiseman J, Melink T, Bell M, et al. Determination of an optimal immunomodulatory dose for cyclophosphamide in combination with interleukin-2 (meeting abstract). Proc Am Assoc Cancer Res 1989; 30: A1501.

    Google Scholar 

  174. Enk CD, Sredni D, Blauvelt A, Katz SI. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J Immunol 1995; 154: 4851–4856.

    PubMed  CAS  Google Scholar 

  175. Evans CH. Lymphotoxin - An immunologic hormone with anti-carcinogenic and anti-tumor activity. Cancer Immunol Immunother 1982; 12: 181.

    Google Scholar 

  176. Fanslow WCK, Clifford K, Vandenbos T, et al. A soluble form of the interleukin 4 receptor in biological fluids. Cytokine 1990; 2: 398.

    PubMed  CAS  Google Scholar 

  177. Fanslow WCK, Clifford K, Park LS, et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 1991; 147:535.

    PubMed  CAS  Google Scholar 

  178. Farrar J, Hilfiker M, Johnson B, et al. Identification of a Tcell derived B-cell growth factor distinct from interleukin-2. J Exp Med 1982; 155:914–923.

    PubMed  Google Scholar 

  179. Farrar MA, Schreiber RD. The molecular biology of interferon y and its receptor. Ann Rev Immunol 1993; 11: 571–611.

    CAS  Google Scholar 

  180. Favre C, Saeland S, Caux C, et al. Interleukin-4 has growth promoting activity on cord blood cells. Blood 1990;75:67–73.

    PubMed  CAS  Google Scholar 

  181. Fernandez-Botran R. Soluble cytokine receptors and their role in immunoregulation. FASEB 1991; 5: 2567.

    CAS  Google Scholar 

  182. Fernandez-Botran R, Vitetta ES. A soluble high affinity interleukin-4 receptor is present in the biological fluids of mice. Proc Nat Acad Sci USA 1990; 87:4202.

    PubMed  CAS  Google Scholar 

  183. Fernandez-Botran R, Vitetta ES. Evidence that soluble interleukin -4 receptors may act as transport proteins. J Exp Med 1991; 174:673.

    PubMed  CAS  Google Scholar 

  184. Fernandez-Botran R, Sanders VM, Oliver KG, et al. Evidence that soluble interleukin-4 receptors may act as transport proteins. J Exp Med 1991; 174: 673.

    PubMed  CAS  Google Scholar 

  185. Ferro TJ, Johnson A, Everitt J, Malik AB. IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes. J Immunol 1989; 142: 1916.

    PubMed  CAS  Google Scholar 

  186. Fildes R. Proleukin - the first interleukin to reach the market? The Clinical Impact of the Interleukins, London, April 10-11, 1989.

    Google Scholar 

  187. Findley HW Jr, Mageed AA, Nasr SA, Ragab AH. Recombinant interleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells. Cancer 1988; 62: 1928.

    PubMed  Google Scholar 

  188. Finke JH, Rayman P, Hart L, et al. Characterization of tumor infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity interferon y secretion and proliferation. J Immunother with Emphasis on Tumor Immunology 1994; 15:91–104.

    CAS  Google Scholar 

  189. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper IV: TH2 clones secrete a factor that inhibits cytokine production by Thl clones. J Exp Med 1989; 170:2081–95.

    PubMed  CAS  Google Scholar 

  190. Fiorentino DF, Zlotnik A, Viera P, et al. IL-10 acts on the antigen presenting cell to inhibit cytokine production by TH1 cells .J Immunol 1991a; 146: 3444–3451.

    PubMed  CAS  Google Scholar 

  191. Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991b; 147: 3815.

    PubMed  CAS  Google Scholar 

  192. Fisher RI, Coltman CA Jr, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokineactivated killer cells. Ann Intern Med 1988; 108: 518.

    PubMed  CAS  Google Scholar 

  193. Flaherty LE, Liu PY, Fletcher WS, et al. Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: Phase II Southwest Oncology Group trial. J Natl Cancer Inst 1992; 84: 893–894.

    PubMed  CAS  Google Scholar 

  194. Flanagan JG, Chan DC, Leder P. Transmembrane form of the kit growth factor is determined by alternative splicing and is missing in the Sid mutant. Cell 1991; 64: 1025–1035.

    PubMed  CAS  Google Scholar 

  195. Fontana A, Kristensen F, Dubs R, et al. Production of prostaglandin E and interleukin-1 like factor by cultured astrocytes and CG glioma cells. J Immunol 1982; 129: 2413–2419.

    PubMed  CAS  Google Scholar 

  196. Ford RJ, Tamayo A, Marker B, Ambrus JL. IL-14 and growth control in human B cell lymphomas. FASEB J 1992; 8: A1021.

    Google Scholar 

  197. Foss FM, Koc Y, Stetler-Stevenson MA, et al. Costimulation of cutaneous T cell lymphoma cells by Interleukin 7 and interleukin 2: potential autocrine and paracrine effectors in the Sezary syndrome. J Clin Oncol 1994; 12:326–335.

    PubMed  CAS  Google Scholar 

  198. Foulke RS, Marshall MH, Trotta PP, vonHoff DD. In vitro assessment of the effects of granulocyte monocyte colony stimulating factor on primary human tumors and derived tumor cell lines. Cancer Res 1990; 50: 6264–6267.

    PubMed  CAS  Google Scholar 

  199. Fountoulakis M, Zulauf M, Lustig A. Stoichiometry of interaction between interferon-y and its receptor Eur J Biochem 1992;209:781–787.

    Google Scholar 

  200. Foxwell BML, Taylor Fishwick DA, Simon JL, et al. Activation induced changes in expression and structure of the IL7 receptor in human T cells. Int Immunol 1992; 4: 277.

    PubMed  CAS  Google Scholar 

  201. Foxwell BM, Willcocks JL, Taylor-Fishwick DA, et al. Inhibition of activation induced changed in the structure of the T cell interleukin-7 receptor by cyclosporin A and FK506. Eur J Immunol 1993; 23: 85–89.

    PubMed  CAS  Google Scholar 

  202. Frank MB, Watson J, Gillis S. Biochemical and biologic characterization of lymphocyte regulatory molecules. VIII. Purification of interleukin-2 from a human T-cell leukemia. J Immunol 1981; 127: 2361.

    PubMed  CAS  Google Scholar 

  203. Fransen L, Van deHayden J, Ruysshaert R, et al. Recombinant tumor necrosis factor: its effects and its synergism with interferon y on a variety of normal and transformed human cell lines. Eur J Cancer and Clin Oncol 1986; 22: 419–426.

    CAS  Google Scholar 

  204. Fraser CC, Thacker JD, Hogge DE, et al. Alterations in lymphopoiesis after hematopoietic reconstitution with IL- 7 virus infected bone marrow. J Immunol 1993; 151: 2409–2418.

    PubMed  CAS  Google Scholar 

  205. Frendl G, Beller DI. Regulation of macrophage activation by IL3.1. IL-3 functions as a macrophage activating factor with unique properties inducing la and lymphocyte function associated antigen 1 but not cytotoxicity. J Immunol 1990; 144: 3392.

    PubMed  CAS  Google Scholar 

  206. Frishman J, Long B, Knospe W, et al. Genes for interleukin 7 are translated in leukemia cell subsets of individuals with chronic lymphocytic leukemia. J Exp Med 1993; 177:955–64.

    PubMed  CAS  Google Scholar 

  207. Fung MC, Hapel AJ, Mymer S, et al. Molecular cloning of cDNA for murine interleukin-3. Nature 1984; 307: 233.

    PubMed  CAS  Google Scholar 

  208. Gajewski TF, Schell SR, Nau G, Fitch FW. Regulation ofT cell activation: differences among T cell subsets. Immunol Rev 1989; 111:79–110.

    PubMed  CAS  Google Scholar 

  209. Galazaka AR, Weiner J, Barth NM, Oldham RK. Lymphokines and cytokines. In: Principles of Cancer Biotherapy, RK Oldham ed. Marcel Dekker Inc., New York, 1991, pp 327–361.

    Google Scholar 

  210. Gallagher G, Stimson WH, Findlay J et al. Interleukin 6 enhances the induction of human lymphokine activated killer cells. Cancer Immunol Immunother 1990; 31:49–52.

    PubMed  CAS  Google Scholar 

  211. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. Exp Med 1990a; 172: 1217–1224.

    CAS  Google Scholar 

  212. Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector mediated y-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990b; 50: 7820–7825.

    PubMed  CAS  Google Scholar 

  213. Garvy BA Riley RL. IFN gamma abrogates IL-7 dependent proliferation in per-B cells coinciding with onset of apoptosis. Immunology 1994; 81: 381–8.

    PubMed  CAS  Google Scholar 

  214. Gastl GA, Abrams JS, Nanus DM, et al. Interleukin 1 production by human carcinoma cell lines and its relationship to interleukin 6 expression. Int J Cancer 1993; 55: 96.

    PubMed  CAS  Google Scholar 

  215. Gately MK, Desai BB, Wolitky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (Cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874–882.

    PubMed  CAS  Google Scholar 

  216. Gately MK, Wilson DE, Wong HL. Synergy between recombinant Interleukin 2 and interleukin 2 depleted lymphokine containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol 1986; 136: 1274.

    PubMed  CAS  Google Scholar 

  217. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin 12. Cellular Immunology 1992; 143: 127–142.

    PubMed  CAS  Google Scholar 

  218. Gaynor ER, Ellis TM, Harris J, et al. Adjuvant immunotherapy using intermittent 24 hour infusions of recombinant interleukin-2 in patients with surgically resected colon carcinoma at high risk for recurrence (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A739.

    Google Scholar 

  219. Gazzinelli RT, Oswald IP, James SL, Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFNy activated macrophages. J Immunol 1992; 148: 1792.

    PubMed  CAS  Google Scholar 

  220. Gearing AJH, Thorpe R. The international standard for human interleukin-2. J Immunol Methods 1988; 114: 3.

    PubMed  CAS  Google Scholar 

  221. Gearing DP, Cameau MR, Friend DJ, et al. The IL-6 signal transducer gpl30: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992; 255: 1434.

    PubMed  CAS  Google Scholar 

  222. Gearing DP, Cosman D. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell 1991; 66: 9.

    PubMed  CAS  Google Scholar 

  223. Geertsen PF, Hermann GG, von der Maase H, Steven K. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single-center phase II study. J Clin Oncol 1992; 10: 753–759.

    PubMed  CAS  Google Scholar 

  224. Gemlo BT, Palladino MA Jr, Jaffe HS, et al. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988; 48: 5864.

    PubMed  CAS  Google Scholar 

  225. Germann T, Gately MK, Schoenhaut DS, et al. Interleukin 12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (TH1) but not TH2 cells. EJ Immunol 1993; 23: 1762–1770.

    CAS  Google Scholar 

  226. Gery I, Gershon RK, Waksman BH. Potentiation of the Tlymphocyte response to mitogens. II. The cellular source of potentiating mediators. J Exp Med 1972; 136: 143.

    PubMed  CAS  Google Scholar 

  227. Ghezzi P, Saccardo B, Villa P, et al. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect Immun 1986; 54: 837–840.

    PubMed  CAS  Google Scholar 

  228. Ghosh AK, Smith K, Prendiville J, et al. A phase-I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer - immunological effects. Eur Cytokine Network 1993; 4: 205–211.

    CAS  Google Scholar 

  229. Gilewski TA, Richards JM, Vogelzang NJ, et al. A phase II study of recombinant interleukin-2 with or without lymphokine activated killer cells in patients with metastatic colon carcinoma (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A499a.

    Google Scholar 

  230. Gill I, Agah R, Mazumder A. Synergistic antitumor effects of interleukin-2 and the monoclonal antibody Lym-1 in vitro and in vivo (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1989; 30: A1445.

    Google Scholar 

  231. Gimbrone MA, Obin MS, Brock AF, et al. Endothelial interleukin 8. a novel inhibitor of leukocyte endothelial interactions. Science 1989; 246: 1601.

    PubMed  CAS  Google Scholar 

  232. Giovarelli M, Musiani P, Modesti A, et al. Local release of IL10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody dependent immune memory. J Immunol 1995; 155: 3112–3123.

    PubMed  CAS  Google Scholar 

  233. Giri JG, Adhieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL2 receptor by the novel cytokine IL-15. EMBO J 1994; 13: 2822–2830.

    PubMed  CAS  Google Scholar 

  234. Go NF, Castle BE, Barrett R, et al. Interleukin 10 (IL-10) a novel B cell stimulatory factor: unresponsiveness of X chromosome linked immunodeficiency B cells. J Exp Med 1990; 172: 1625–1631.

    PubMed  CAS  Google Scholar 

  235. Godfrey DI, Gately M, Zlotnik A. Influence of IL-12 on intrathymic T cell development. J Immunol 1993; 150: 11A.

    Google Scholar 

  236. Goldstein D, Sosman J, Hank J, et al. Repetitive weekly cycles of interleukin-2: Outpatient treatment with a lower dose of IL-2 maintains heightened NK and LAK activity (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A751.

    Google Scholar 

  237. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal caner by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716.

    PubMed  CAS  Google Scholar 

  238. Goodwin RG, Friend D, Ziegler SF, et al. Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990; 60,941.

    PubMed  CAS  Google Scholar 

  239. Goodwin RG, Lupton GS, Schmierer A, et al. Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Nat Acad Sci USA 1989; 86: 302.

    PubMed  CAS  Google Scholar 

  240. Gordon J, Guy GR. The molecules controlling B lymphocytes. Immunol Today 1987; 8: 339.

    CAS  Google Scholar 

  241. Gordon J, MacLean LD. A lymphocyte stimulating factor produced in vitro. Nature 1965; 208: 795–796.

    PubMed  CAS  Google Scholar 

  242. Gottlieb DJ, Brenner MK, Heslop HE, et al. A phase I clinical trial of recombinant interleukin 2 following high dose chemoradiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 1989; 60: 610.

    PubMed  CAS  Google Scholar 

  243. Gottlieb DJ, Prentice HG, Heslop HE, et al. Effects of recombinant interleukin-2 administration on cytotoxic function following high dose chemo-radiotherapy for haematological malignancy. Blood 1989; 74: 2335.

    PubMed  CAS  Google Scholar 

  244. Gough NM, Gough J, Metcalf D. Molecular cloning of cDNA encoding a murine hematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 1984; 309: 763.

    PubMed  CAS  Google Scholar 

  245. Grabstein K, Eisenman J, Mochizuki D, et al. Purification to homogeneity of B-cell stimulating factor: a molecule that stimulates proliferation of multiple lymphokine dependent cell lines. J Exp Med 1986; 163: 1405–1414.

    PubMed  CAS  Google Scholar 

  246. Grabstein K, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the B-chain of the interleukin 2 receptor. Science 1994; 264: 965–968.

    PubMed  CAS  Google Scholar 

  247. Grabstein KH, Namen AE, Shanebeck K, et al. Regulation of human T cell proliferation by IL7. J Immunol 1990; 144:3015–3020.

    PubMed  CAS  Google Scholar 

  248. Grabstein KH, Park LS, Morrissey JP, et al. Regulation of T cell proliferation by T cell stimulating factor-1. J. Immunol 1987; 139: 1148–1153.

    PubMed  CAS  Google Scholar 

  249. Granger GA, Williams TW. Lymphocyte cytotoxicity in vitro: Activation and release of a cytotoxic factor. Nature 1968; 218: 1253.

    PubMed  CAS  Google Scholar 

  250. Granowitz EV, et al. J Biol Chem 1991;266: 14147.

    PubMed  CAS  Google Scholar 

  251. Gray PW, Aggarwal BB, Bentor CV, et al. Cloning and expression of cDNA for human lymphotoxin a lymphokine with tumor necrosis activity. Nature 1984; 312: 721–724.

    PubMed  CAS  Google Scholar 

  252. Green S, Dobrjansky A, Chiasson MA, et al. Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst 1977; 59: 1519.

    PubMed  CAS  Google Scholar 

  253. Greil J, Gramatzki M, Burger R, et al. The acute lymphoblastic leukemia cell line SEM with t(4; 11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. British J Haematology 1994; 86: 275–283.

    CAS  Google Scholar 

  254. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. J Exp Med 1982;155: 1823.

    PubMed  CAS  Google Scholar 

  255. Grubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Nat Acad Sci USA 1991; 88:4143–4147.

    Google Scholar 

  256. Gustavson LE, Nadeau RW, Oldfield NF. Pharmacokinetics of Teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer. J Biol Response Modif 1989; 8: 440.

    CAS  Google Scholar 

  257. Guy GR, Chua SP, Wong NS, et al. Interleukin 1 and tumor necrosis factor activate common multiple protein kinases in human fibroblasts. J Biol Chem 1991; 266: 14343–14352.

    PubMed  CAS  Google Scholar 

  258. Hamid Q, Barkans J, Meng Q, et al. Human eosinophils synthesize and secrete Interleukin 6 in vitro. Blood 1992; 80: 1496.

    PubMed  CAS  Google Scholar 

  259. Han X, Itoh K, Balch CM, Pellis JH. Recombinant interluekin-4 (RIL-4) inhibits interleukin 2 induced activation of peripheral blood lymphocytes. Lymphokine Cytokine Res 1988; 7: 227–234.

    CAS  Google Scholar 

  260. Hank JA, Kohler PC, Hillman GW, et al. Interleukin-2 dependent human lymphokine activated killer cells generated in vivo during administration of human recombinant IL-2. Cancer Res 1988; 48: 1965.

    PubMed  CAS  Google Scholar 

  261. Haranaka K, Satomi N, Sakurai A. Antitumor activity of TNF against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984;34: 263.

    PubMed  CAS  Google Scholar 

  262. Hedrick SM, Cohen D, Nieson E, et al. Isolation of cDNA clones encoding T-cell specific membrane association proteins. Nature 1984; 308: 149.

    PubMed  CAS  Google Scholar 

  263. Hefeneider S, Conlon P, Henney C, et al. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T-lymphocytes and resident natural killer cells. J Immunol 1983; 130: 222.

    PubMed  CAS  Google Scholar 

  264. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature 1981; 291: 335.

    PubMed  CAS  Google Scholar 

  265. Herbelin A, Machzvoine F, Schneider E, et al. IL-7 is requisite for IL-1 induced thymocyte proliferation. Involvement of IL-7 in the synergistic effects of granulocyte macrophage colony stimulating factor or tumor necrosis factor with IL-1. J Immunol 1992; 148: 99–105.

    PubMed  CAS  Google Scholar 

  266. Herbert JM, Savi P, Laplace M-C, et al. IL4 and ILl3 exhibit comparable abilities to produce pyrogen induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett 1993; 328: 268.

    PubMed  CAS  Google Scholar 

  267. Hercend T, Meuer SC, Reinherz EL, et al. Generation of a cloned NK cell line from the ’null cell’ fraction of human peripheral blood. J Immunol 1982; 129: 1299.

    PubMed  CAS  Google Scholar 

  268. Heslop HE, Gottlieb DJ, Bianchi ACM, et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374.

    PubMed  CAS  Google Scholar 

  269. Heufler C, Koch F, Schuler G. Granulocyte macrophage colony stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp Med 1988; 167:700.

    PubMed  CAS  Google Scholar 

  270. Heufler C, Topar G, Grasseger A, et al. Interleukin 7 is produced by murine and human keratinocytes. J Exp Med 1993;178: 1109–1114.

    PubMed  CAS  Google Scholar 

  271. Hibi K, Takahashe T, Sekido Y, et al. Coexpression of the stem cell factor and the c-kit genes in small cell lung cancer. Oncogene 1991; 6: 2291–2296.

    PubMed  CAS  Google Scholar 

  272. Hickman CJ, Crim JA, Mostowski HS, Siegel JP. Regulation of human cytotoxic T lymphocyte development by interleukin-7. J Immunol 1990; 145: 2415–2420.

    PubMed  CAS  Google Scholar 

  273. Higuchi CM, Thompson JA, Lindgren CG, et al. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vitro or in vivo. Cancer Res 1989; 49: 6487–6492.

    PubMed  CAS  Google Scholar 

  274. Hill RJ, Warren MK, Levin J. Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest 1990; 85: 1242.

    PubMed  CAS  Google Scholar 

  275. Hirano T, Matsuda T, Nakajima K. Signal transduction through gpl30 that is shared among the receptors for the interleukin related cytokine subfamily. Stem Cells 1994; 12:262–277.

    PubMed  CAS  Google Scholar 

  276. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin Nature 1986; 324: 73–76.

    PubMed  CAS  Google Scholar 

  277. Hoch H, Dorsch M, Diamantstein T, Blankenstien T. Interleukin 7 induces CD4+ T cell dependent tumor rejection. J Exp Med 1991; 174: 1291–1298.

    Google Scholar 

  278. Hoch H, Dorsch M, Kunzendorf U, et al. Vaccination with tumor cells genetically engineered to produce different cytokines: effectively not superior to a classical adjuvant. Cancer Res 1993; 53: 1–8.

    Google Scholar 

  279. Hoch H, Dorsch M, Kunzendorf U, et al. Mechanism of the rejection induced by tumor cell targeted gene transfer of interleukin 2, interleukin 4, interleukin 7 tumor necrosis factor or interferon y. Proc Nat Acad Sci USA 1993; 90: 2774–2778.

    Google Scholar 

  280. Hohmann HP, Remy R, Brockhaus M, et al. Two different cell types have different receptors for tumor necrosis factor (TNFa). J Biol Chem 1989; 264: 14927–14934.

    PubMed  CAS  Google Scholar 

  281. Holbrook ST, Ohls RK, Schibler KR, et al. Effect of interleukin 9 on clonogenic maturation and cell cycle status of fetal and adult hematopoietic progenitors. Blood 1991;77:2129–2134.

    PubMed  CAS  Google Scholar 

  282. Holmes WE, Lee J, Kuang WJ, et al. Structure and functional expression of a human interleukin-8 receptor. Science 1991; 253: 1278.

    PubMed  CAS  Google Scholar 

  283. Hoon DSB, Banex M, Okun E, et al. Modulation of human melanoma cells by interleukin-4 and in combination with y-interferon or a-tumor necrosis factor. Cancer Res 1991; 51: 2002–2008.

    PubMed  CAS  Google Scholar 

  284. Hoon DSB, Edward O, Banez M, et al. Interleukin 4 alone and with y-interferon or tumor necrosis factor inhibits the growth and modulates cell surface antigens on human renal cell carcinoma. Cancer Res 1991; 51: 5687–5693.

    PubMed  CAS  Google Scholar 

  285. Horton SA, Oldham RK, Yannelli JR. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin-2. Cancer Res 1990; 50: 1686–1692.

    PubMed  CAS  Google Scholar 

  286. Hossiau FA, Renauld JC, Stevens M, et al. Human T cell lines and clones respond to IL 9. J Immunol 1993; 150: 2634–2640.

    Google Scholar 

  287. Howard M, Hilfiker M, Johnson B, et al. Identification of a T cell derived B cell growth factor distinct from Interleukin-2. J Exp Med 1982; 155: 914–923.

    PubMed  CAS  Google Scholar 

  288. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through ILl2 produced by Listerialinduced macrophages. Science 1993; 260: 547–9.

    PubMed  CAS  Google Scholar 

  289. Hsu D-H, deWaal Malefyt R, Fiorentino DF, et al. Expression of interleukin 10 activity by Epstein Barr virus protein BCRFI. Science 1990; 250: 830–832.

    PubMed  CAS  Google Scholar 

  290. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded at the SI locus and is the ligand of the c kit receptor the gene product of the W locus. Cell 1990; 63: 225–233.

    PubMed  CAS  Google Scholar 

  291. Huber AR, Kunkel SL, Todd RF, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991; 254: 99.

    PubMed  CAS  Google Scholar 

  292. Huland E, Huland H. Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 1989; 49: 5469.

    PubMed  CAS  Google Scholar 

  293. Huland E, Huland H, Heinzer H. Interleukin-2 by inhalation: Local therapy for metastatic renal cell carcinoma. U Urol 1992; 13\47: 344–348.

    Google Scholar 

  294. Hu-Li J, Shevach EM, Mizuguchi J, et al. B cell stimulatory factor-1 (interleukin-4) is a potent costimulant for normal resting T lymphocytes. J Exp Med 1987; 165:157–172.

    PubMed  CAS  Google Scholar 

  295. Hultner L, Druez C, Moeller J, et al. Mast cell growth enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGF1II. Eur J Immunol 1990; 20: 1413–1416.

    PubMed  CAS  Google Scholar 

  296. Hunninghake GW, Glazier MM, Monick MM, Dinarello CR. Interleukin-1 is a chemotactic factor for T lymphocytes. Am Rev Respir Dis 1987; 135: 66.

    PubMed  CAS  Google Scholar 

  297. Hunter CA, Chizzonite R, Remmington JS. IL-1 (3 is required for IL-12 to induce production of IFNy by NK cells. J Immunol 1995; 155:4347–4354.

    PubMed  CAS  Google Scholar 

  298. Hutchins D, Steel CM. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast derived factors. Int J Cancer 1994; 58: 80–84.

    PubMed  CAS  Google Scholar 

  299. Ihle JN, Keler J, Oroszlan S, et al. Biological properties of homogenous interleukin-3. J Immunol 1983; 131: 282.

    PubMed  CAS  Google Scholar 

  300. Ihle JN, Keler J, Oroszlan S et al. Biological properties of interleukin-3. J Immunol 1983; 131: 282.

    PubMed  CAS  Google Scholar 

  301. Ihle JN, Witthuhn BA, Yamamoto K, et al. Signaling by the cytokine superfamily: JAKs and STATs. Trends in Biochemical Sciences 1994; 19: 222–227.

    PubMed  CAS  Google Scholar 

  302. Iho S, Shau HY, Golub SH. Characteristics of Interleukin 6 enhanced lymphokine activated killer cell function. Cell Immunol 1991; 135:66–77.

    PubMed  CAS  Google Scholar 

  303. Iigo M, Sakurai M, Tamura T, et al. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988; 48: 260.

    PubMed  CAS  Google Scholar 

  304. Ilson D, Motzer R, Kradin R, et al. A phase-II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 1992; 10: 1124–1130.

    PubMed  CAS  Google Scholar 

  305. Imai Y, Nara N, Tohda S, et al. Antiproliferative and differentiative effects of recombinant interleukin-4 on a G-CSF-stimulating-dependent myeloblasts leukemic cell line. Blood 1991; 78:471–478.

    PubMed  CAS  Google Scholar 

  306. Inoue M, Kyo S, Fujita M, et al. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors Cancer Res 1994; 54: 3049–3053.

    PubMed  CAS  Google Scholar 

  307. Isaacs A, Lindenman J. Virus interference. Proc R Soc 1957; 147:258–267.

    CAS  Google Scholar 

  308. Iscove NN. Erythropoietin independent stimulation of early erythropoiesis in adult marrow cultures byconditioned medium of lectin stimulated mouse spleen cells. In: Golde D, Kline MJ, Metcalf D, Fox CF, eds. Hematopoietic Cell Differentiation. Academic Press, New York pp 37-52.

    Google Scholar 

  309. Ito R, Kitadai Y, Kyo E, et al. Interleukin 1 acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res 1994; 54:4102–41206.

    Google Scholar 

  310. Jacobsen FW, Veiby OP Jacobsen SE. IL-7 stimulates CSF-induced proliferation of murine bone marrow macrophages and Mac-1+ myeloid progenitors in vitro. J Immunol 1994; 153: 270–276.

    PubMed  CAS  Google Scholar 

  311. Jadus MR, Schmunk G, Djeu JY, Parkman RJ. Morphology and mechanism of interleukin 3 dependent natural cytotoxic cells: tumor necrosis factor as a possible mediator. Immunol 1986; 137: 2774–.

    Google Scholar 

  312. Jadus MR, Good RW, Crumpacker DB, Yannelli JR. Effects of Interleukin 4 upon human tumoricidal cells obtained from patients bearing solid tumors. J Leukocyte Biol 1991; 49: 139–151.

    PubMed  CAS  Google Scholar 

  313. Jadus MR, Schmunk G, Djeu JY. Morphology and lytic mechanisms of interleukin 3 dependent natural cytotoxic cells: tumor necrosis factor as their probable mode of action. J Immunol 1986; 136: 783.

    PubMed  CAS  Google Scholar 

  314. Jadus MR, Parkman R. The selective growth of murine newborn-derived suppressor cells and their probable mode of action. J Immunol 1986; 136: 783.

    PubMed  CAS  Google Scholar 

  315. Jelinek DF, Splawski JB, Lipsky PE. The roles of IL-2 and IFNy in human B cell activation, growth and differentiation. Eur J Immunol 1986; 16: 925.

    PubMed  CAS  Google Scholar 

  316. Jelinek DF and Braten JK. Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol 1995; 154: 1606.

    PubMed  CAS  Google Scholar 

  317. Jinquan T, Larsen CG, Gesser B, et al. Human IL-10 is a chemoattractant for CD8+T lymphocytes and an inhibitor of IL-8-Induced CD4+ T lymphocyte migration. J Immunol 1993; 151:4545–51.

    PubMed  CAS  Google Scholar 

  318. Jinquan T, Deleuran B, Gesser B, et al. Regulation of human T lymphocyte chemotaxis in vitro by T cell derived cytokines IL-2, IFN-A,, IL-4, IL-10, and IL-13. J Immunol 1995;154:3742–3752.

    CAS  Google Scholar 

  319. Johnson CS, Chang MJ, Braunschweiger PG, Furmanski P. Acute hemorrhagic necrosis of tumors induced by interleukin-la: effects independent of tumor necrosis factor .J Natl Cancer Inst 1991; 83: 842–848.

    PubMed  CAS  Google Scholar 

  320. Kaashoek JG, Mout JR, Falkenburg JHF, et al. Cytokine production by the bladder carcinoma cell line 5637. Lymphokine Cytokine Res 1991; 10: 231.

    PubMed  CAS  Google Scholar 

  321. Katz A, Shulaman LM, Revel M, et al. Combined therapy with IL6 and inactivated tumor cell suppressed metastasis in mice bearing 3LL lung carcinomas. Int J Cancer 1993; 53:812–818.

    PubMed  CAS  Google Scholar 

  322. Katz A, Schulman LM Porgador A et al. Abrogation of B16 melanoma metastases by long term low dose interleukin 6 therapy. J Immunother 1993; 13: 98–109.

    CAS  Google Scholar 

  323. Kawakami M, Cerami A. A study of endotoxin induced decrease of lipoprotein lipase activity. J Exp Med 1981; 154:631–639.

    PubMed  CAS  Google Scholar 

  324. Kawakami Y, Custer M, Rosenberg SA, Lotze M. Interleukin- 4 regulates Interleukin-2 induction of lymphokine activated killer activity from human leukocytes. J Immunol 1989; 142:3452.

    PubMed  CAS  Google Scholar 

  325. Kawakami Y, Haas, GP, Lotze MT. Expansion of tumor infiltrating lymphocytes from human tumors using the T cell growth factors interleukin-2 and interleukin-4. J Immunotherapy 1993; 14; 336–347.

    CAS  Google Scholar 

  326. Kawakami Y, Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumor infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988;168:2183–91.

    PubMed  CAS  Google Scholar 

  327. Kawano M, Hirano T, Matsuda T et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–85.

    PubMed  CAS  Google Scholar 

  328. Kawano M, Matsushima K, Masuda A, et al. A major 50 kDa human B cell growth factor II induces both Tac antigen expression and proliferation by several lymphocytes. Cell Immunol 1988; 111: 273–286.

    PubMed  CAS  Google Scholar 

  329. Kawasakura S, Lowenstein L. A factor stimulating DNA synthesis derived from the medium of leucocyte cultures. Nature 1965; 208: 794–795.

    Google Scholar 

  330. Kawase I, Komuta K, Hara H, et al. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an anti-tumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 1988; 48: 1173.

    PubMed  CAS  Google Scholar 

  331. Kawashima I, Ohsumi J, Mita-Honjo K, et al. Molecular cloning of the cDNA encoding adipogenesis inhibitory factor and identity with interleukin 11. FEBS Lett 1991; 283: 199–202.

    PubMed  CAS  Google Scholar 

  332. Kaye J, Gillis S, Mizel SB, et al. Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol 1984; 133:1339–1345.

    PubMed  CAS  Google Scholar 

  333. Kedar E, Ben-Aziz R, Epstein E, Leshem B. Chemoimmunotherapy of murine tumors using interleukin-2 (IL- 2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type. Cancer Immunol Immunother 1989; 29: 74.

    PubMed  CAS  Google Scholar 

  334. Keegan AD, Pierce JH. The interleukin-4 receptor: signal transduction by a hematopoietin receptor. J Leuk Biol 1994;5:272–279.

    Google Scholar 

  335. Kehri JH, Dukovich M, Whalen G, et al. Novel interleukin 2 receptor appears to mediate IL2-induced activation of natural killer cells J Clin Invest 1988; 81: 779.

    Google Scholar 

  336. Kelley VE, Gaulton GN, Hattori M, et al. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 1988; 140: 59.

    PubMed  CAS  Google Scholar 

  337. Kemeny L, Ruzicka T, Dobozy A, Michel G. Role of Interleukin 8 receptor in skin. International Arch Allergy and Immunology 1994; 104: 317–322.

    CAS  Google Scholar 

  338. Kern P, Toy J, Dietrich M. Preliminary clinical observation with recombinant interleukin 2 in patients with AIDS or LAS. Blut 1985; 50: 1.

    PubMed  CAS  Google Scholar 

  339. Kiniwa M, Gately M, Grubler U, et al. Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest 1992; 90: 262–266.

    PubMed  CAS  Google Scholar 

  340. Kirnbauer R, Charvat B, Schauer E, et al. Modulation of intracellular adhesion molecule 1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7 TNFp, and UVB light. J Invest Dermat 1992; 98: 320–326.

    CAS  Google Scholar 

  341. Kirken RA, Rui H, Howard OM, Farrar WL. Involvement of JAK-family tyrosine kinases in hematopoietin receptor signal transduction. Prog Growth Factor Res 1994; 5: 195–211.

    PubMed  CAS  Google Scholar 

  342. Kishimoto T, Akira S, Taga T. Interleukin 6 and its receptor: a paradigm for cytokines. Science 1992; 258: 593–597.

    PubMed  CAS  Google Scholar 

  343. Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Ann Rev Immunol 1988; 6:485–512.

    CAS  Google Scholar 

  344. Kita HT, Onishi T, Okubo Y, et al. Granulocyte /macrophage colony stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991; 174:745.

    PubMed  CAS  Google Scholar 

  345. Klasa RJ, Silver HKB. Phase 1-2 trial of interleukin-2 splenic artery perfusion in advanced malignancy (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A686.

    Google Scholar 

  346. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989; 170: 827–845.

    PubMed  CAS  Google Scholar 

  347. Koch AE, Polverini PK, Kunkel SL, et al. Interleukin 8 as a macrophage derived mediator of angiogenesis. Science 1992;258: 1798–1801.

    PubMed  CAS  Google Scholar 

  348. Koettnitz K and Kalthoff FS. Human interleukin 4 receptor signalling requires sequences contained within two cytoplasmic regions. EJ Immunol 1993; 23: 988–991.

    CAS  Google Scholar 

  349. Koi A. The role of interleukin 6 as the hepatocyte stimulating factor in the network of inflammatory cytokines. Ann NY Acad Sci 1989; 557: 1–8.

    Google Scholar 

  350. Kolitz JE, Wong GY, Welte K, et al. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. J Biol Response Modif1988 7: 457.

    CAS  Google Scholar 

  351. Komschlies KL, Back TT, Gregorio TA, et al. Effects of rhIL7 on leukocyte subsets in mice: implications for antitumor activity. Immunology 1994; 61: 95–104.

    CAS  Google Scholar 

  352. Kondo M, Takeshita T, Higuchi M, et al. Functional participation of the IL2 receptor gamma chain in IL-7 receptor complexes. Science 1994; 263: 1453–1454.

    PubMed  CAS  Google Scholar 

  353. Konrad MW, Bradley EC. The pharmacokinetics of a recombinant IL-2 muteine given by five routes in a number of phase I trials (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1986; 5: A920.

    Google Scholar 

  354. Koo AS, Armstrong C, Bochner B, et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother 1992; 35: 97–105.

    PubMed  CAS  Google Scholar 

  355. Kos F J, Mullbacher A. IL2 independent activity of IL-7 in the generation of secondary antigen-specific cytotoxic T cell responses in vitro. J Immunol 1993; 150: 387–393.

    PubMed  CAS  Google Scholar 

  356. Kotasek D, Vercellotti GM, Ochoa AC, et al. Mechanism of cultured endothelial injury induced by lymphokineactivated killer cells. Cancer Res 1988; 48: 5528.

    PubMed  CAS  Google Scholar 

  357. Kotowicz K, Callard RE. Human immunoglobulin class and IgG subclass regulation: dual action of interleukin 4. Eur J Immunol 1993; 23: 2250.

    PubMed  CAS  Google Scholar 

  358. Kovacs EJ, Beckner SK, Longo DL, et al. Cytokine gene expression during the generation of human lymphokineactivated killer cells: early induction of interleukin 1-beta by interleukin 2. Cancer Res 1989; 49: 940.

    PubMed  CAS  Google Scholar 

  359. Kradin RL, Boyle LA, Preffer FI, et al. Tumor-derived interleukin-2 dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 1987; 24:76.

    PubMed  CAS  Google Scholar 

  360. Kradin RL, Kurnick JT, Lazarus DS, et al. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989; 1: 577–580.

    PubMed  CAS  Google Scholar 

  361. Krigel RL, Padavic-Shaller KA, Rudolph AR, et al. A Phase I study of recombinant interleukin 2 plus recombinant beta-interferon. Cancer Res 1988; 48: 3875.

    PubMed  CAS  Google Scholar 

  362. Kruse N, Tony HP, Sebald W. Conversion of human interleukin 4 into a high affinity antagonist by a single amino acid replacement. EMBO Journal 1992; 11: 3237–3244.

    PubMed  CAS  Google Scholar 

  363. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994; 180:211–22.

    PubMed  CAS  Google Scholar 

  364. Kuhn R, Rajewski K, Muller W. Generation and analysis of Interleukin-4 deficient mice. Science 1991; 254: 707–709.

    PubMed  CAS  Google Scholar 

  365. Kupper T, Horowitz M, Lee F, et al. Autocrine growth of T cells independent of growth factor for a cloned antigen specific helper T cell. J Immunol 1987; 138: 4280.

    PubMed  CAS  Google Scholar 

  366. Kuribayshi K, Gillis S, Kern D, et al. Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J Immunol 1981; 126: 2321.

    Google Scholar 

  367. Kurt-Jones EA, Beller DI, Mizel SB, Unanui ER. Identification of a membrane-associated interleukin 1. Proc Natl Acad Sci (USA) 1985; 82: 1204–1208.

    CAS  Google Scholar 

  368. Kurt-Jones EA, Hamburg S, Ohara J, et al. Heterogeneity of helper/inducer T lymphocytes. J Exp Med 1987; 166: 1774–1787.

    PubMed  CAS  Google Scholar 

  369. Lachman LB, Dinarello CA, Llanska ND, Fidler IJ. Natural and recombinant human interleukin-lp is cytotoxic for human melanoma cells. J Immunol 1986; 136: 3098–3103.

    PubMed  CAS  Google Scholar 

  370. Langer JA, Pestka S. Interferon Receptors. Immunol Today 1989; 12: 393–400.

    Google Scholar 

  371. Larsen CG, Anderson AO, Oppenheim J J, Matsushima K. The neutrophil activating protein (NAP-1) is also chemotactic forT lymphocytes. Science 1989; 243: 1464.

    PubMed  CAS  Google Scholar 

  372. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K. Production of Interleukin 8 by human dermal fibroblasts and keratinocytes in response to interleukin 1 or tumor necrosis factor. Immunology 1989; 68: 31.

    PubMed  CAS  Google Scholar 

  373. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: Cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234–248.

    PubMed  CAS  Google Scholar 

  374. Lee J, Horuk R, Rice GC, et al. Characterization of two high affinity human interleukin-8 receptors J Biol Chem 1992;267: 16283.

    PubMed  CAS  Google Scholar 

  375. Lee KH, Talpaz M, Rothberg JM, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon a-2A in cancer patients: a phase I study. J Clin Oncol 1989; 7: 1726–1732.

    PubMed  CAS  Google Scholar 

  376. Lee SH, Aggarwal BB, Rinderknecht E, et al. The synergistic antiproliferative effect of gamma-interferon and human lymphotoxin. J Immunol 1984; 133: 1083.

    PubMed  CAS  Google Scholar 

  377. Lee SW, Tsou AP, Chan H, et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beat mRNA. Proc Natl Acad Sci (USA) 1988; 85: 1204–1208.

    CAS  Google Scholar 

  378. Legha S, Ring S, Bedikian A, et al. Biochemotherapy using interleukin-2 + interferon alpha-2a (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma. Melanoma Research 1993; 3: 32.

    Google Scholar 

  379. Lembersky B, Baldisseri M, Kunschner A, et al. Phase I-II study of IP low dose interleukin-2 in refractory stage III ovarian cancer (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A636.

    Google Scholar 

  380. Leonard WJ, Noguchi M, Russel SM, McBride OW. The molecular basis of severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. Immunological Reviews 1994; 138:61–86.

    PubMed  CAS  Google Scholar 

  381. Levitsky JW, Simons H, Vogelstein B, Frost P. Interleukin 2 produced by tumor cell bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403.

    PubMed  Google Scholar 

  382. Lewko WM, Good, RW, Bowman D, et al. Growth of tumor derived activated T cells for the treatment of cancer. Cancer Biotherapy 1994; 9(3) 211–224.

    PubMed  CAS  Google Scholar 

  383. Lewko WM, Smith TL, Bowman DJ, et al. Interleukin-15 and the growth of tumor derived activated T-cells. Cancer Biotherapy 1995; 10: 13–20.

    PubMed  CAS  Google Scholar 

  384. Li WY, Lusheng S, Kanbour A, et al. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor and interleukin 2 in the generation of CD8-I- effectors from tumor infiltrating lymphocytes. Cancer Res 1989; 49: 5979.

    Google Scholar 

  385. Libby P, Warner SJC, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988; 81:487–498.

    PubMed  CAS  Google Scholar 

  386. Lichtman A, Kurt-Jones E, Abbas A. B cell stimulatory factor 1 and not interleukin 2 is and autocrine growth factor for some helper T lymphocytes. Proc Nat Acad Sci 1987; 84:824.

    PubMed  CAS  Google Scholar 

  387. Lindemann A, Hoeffken K, Schmidt RE, et al. A Phase II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 1989; 28:275.

    PubMed  CAS  Google Scholar 

  388. Lindgren CG, Thompson JA, Higuchi CM, Fefer A. Growth and autologous tumor lysis by tumor infiltrating lymphocytes from metastatic melanoma expanded in interleukin 2 or interleukin 2 plus Interleukin 4. J. Immunother 1993; 14: 322–328.

    CAS  Google Scholar 

  389. Lindqvist C, Ostman AL, Okerblom C, Akerman K. Decreased interleukin-2 beta chain receptor expression by interleukin-4 on LGL: influence on the IL-2 induced cytotoxicity and proliferation. Cancer Lett 1992; 64: 43–49.

    PubMed  CAS  Google Scholar 

  390. Liu J, Modrell B, Aruffo A, et al. Interaction between oncostatin M and the signal transducer, gpl30. Cytokine 1994;6:272–278.

    PubMed  CAS  Google Scholar 

  391. Loetscher H, Pan TC, Lahm HW, et al. Molecular cloning and expression of the human 55kd tumor necrosis factor receptor. Cell 1990; 61:351.

    PubMed  CAS  Google Scholar 

  392. Logan TF, Bishop M, Mintun MA, et al. Phase I trial of interleukin-la and carboplatin in patients with metastatic disease to the lung: effects on tumor blood flow evaluated by positron emission tomography. Proc ASCO 1994; 35: 198.

    Google Scholar 

  393. Londei M, Verhoef A, Hawrylowicz C, et al. Interleukin 7 is a growth factor for mature human T cells. Eur J Immunol 1990; 20:425–428.

    CAS  Google Scholar 

  394. London L, Perussiia B, Trinchieri G. Induction and proliferation in vitro of resting human natural killer cells: expression of surface activation antigens J Immunol 1985; 134:718.

    PubMed  CAS  Google Scholar 

  395. Lopez AF, Sanderson CJ, Gamble JR, et al. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167: 219.

    PubMed  CAS  Google Scholar 

  396. Lorenz JJ, Furdon PJ, Taylor JD, et al. A cyclic 3’5’- monophosphate signal is required for the induction of IL- 1 (3 by TNF-a in human monocytes. J Immunol 1995; 155: 836–844.

    PubMed  CAS  Google Scholar 

  397. Lorenzen J, Lewis CE, McCracken D, et al. Human tumor associated NK cells secrete increased amounts of interferon-y and interleukin-4. British J Cancer 1991; 64: 457–462.

    CAS  Google Scholar 

  398. Lotze MT, Frana LW, Sharrow SO, et al. In vivo administration of purified human interleukin 2.1. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 1985; 134: 157.

    PubMed  CAS  Google Scholar 

  399. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant interleukin 2. J Immunol 1985; 135:2865–2875.

    PubMed  CAS  Google Scholar 

  400. Lotze MT, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764.

    PubMed  CAS  Google Scholar 

  401. Lotze M, Jirik F, Kabouridis P, et al. B cell stimulating factor-2/interleukin 6 is a co-stimulant for human thymocytes and T lymphocytes. J Exp Med 1988; 167: 1253–1258.

    Google Scholar 

  402. Lotze M. Role of IL-4 in the antitumor response. IL-4: Structure and Function (H Spits ed), CRC Press, Boca Raton, FL 1992; 111: 274-280.

    Google Scholar 

  403. Lotze MT, Robb R, Sharrow SO, et al. Systemic administration of interleukin-2 in humans. J Biol Response Modif 1984; 3:475.

    CAS  Google Scholar 

  404. Lotzova E, Savary CA, Herberman RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 1987; 138: 2718.

    PubMed  CAS  Google Scholar 

  405. Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Nat Acad Sci USA 1992; 89: 9215–9219.

    PubMed  CAS  Google Scholar 

  406. Lu C, Kerbel RS. Interleukin 6: undergoes transition from paracrine growth inhibitor to autocrine growth stimulator during human melanoma progression. J Cell Biol 1993; 120: 1281–1288.

    PubMed  CAS  Google Scholar 

  407. Luger TZ, Stadler BM, Katz SI, et al. Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). J Immunol 1981; 127: 1493–1498.

    PubMed  CAS  Google Scholar 

  408. Luo H, Rubio M, Biron G, et al. Antiproliferative effect of interleukin-4 in B chronic lymphocytic leukemia. Blood 1991; 10:418–425.

    CAS  Google Scholar 

  409. Luscher U, Filgueira L, Juretic A, et al. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor infiltrating lymphocytes. Int J Cancer 1994; 57: 612.

    PubMed  CAS  Google Scholar 

  410. Lynch DH and Miller RE. Induction of murine lymphokine activated killer cells by recombinant IL-7. J Immunol 1990; 145: 198.

    Google Scholar 

  411. Lynch DH and Miller RE. Interleukin 7 promotes Long term in vitro growth and antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med 1994; 179:31–42.

    PubMed  CAS  Google Scholar 

  412. Macatonia SE, Doherty TM, Knight SC, O’Garra A. Differential effect of IL-10 on dendritic cell induced T cell proliferation and IFN-gamma production. J Immunol 1993; 150:3755–3765.

    PubMed  CAS  Google Scholar 

  413. Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Thl cells form naive CD4+ T cells J Immunol 1995; 154: 5071–5079.

    PubMed  CAS  Google Scholar 

  414. MacGlashan D Jr, White JM, Huang S, et al. Secretion of IL4 from human basophils. J Immunol 1994; 152: 3006.

    PubMed  CAS  Google Scholar 

  415. MacNeil IA, Suda T, Moore KW, et al. IL-10, a novel growth factor for mature and immature T cells. J Immunol 1990; 145:4167.

    PubMed  CAS  Google Scholar 

  416. Maleckar JR, Fridell CS, Lewko WM, et al. Tumor derived activated cells: cell culture conditions and characterization. In : Stevenson HC (Ed) Adoptive cellular immunotherapy of cancer. Marcel Dekker, Inc. New York. 1989. pl59–173.

    Google Scholar 

  417. Maleckar JR, Fridell CS, Sferruzza A, et al. Activation and Expansion of tumor derived activated cells (TDAC). J Nat Cancer Inst 1989; 1: 1655–1660.

    Google Scholar 

  418. Maliszewski CR, Sato TA, VandenBos T, et al. Cytokine Receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-4 and IL-4 induced B cell activities in vitro. J Immunol 1990; 144: 3028.

    PubMed  CAS  Google Scholar 

  419. Malkovsky M, Loveland B, North M, et al. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature 1987; 325: 262.

    PubMed  CAS  Google Scholar 

  420. Manabe A, Cousan-Smith E, Kumagai M, et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high risk acute lymphoblastic leukemia. Blood 1994;83:1731–1737.

    PubMed  CAS  Google Scholar 

  421. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-y are two necessary cytokines in the development of cytotoxic T cells. J Immunol 1989; 143: 1210–1214.

    PubMed  CAS  Google Scholar 

  422. March CJ, Mosley B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315: 641–647.

    PubMed  CAS  Google Scholar 

  423. Marcus PI. Interferon induction of viruses: double stranded ribonucleic acid as the common proximal molecules. Interferons. 1985; 3: 113–175.

    Google Scholar 

  424. Margolin K, Aronson FR, Sznol M, et al. Phase II studies of recombinant human IL-4 in advanced renal cancer and malignant melanoma. J Immunother 1994; 15: 147–153.

    CAS  Google Scholar 

  425. Margolin KA, Rayner A A, Hawkins MJ, et al. Interleukin- 2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7: 486.

    PubMed  CAS  Google Scholar 

  426. Marolda R, Belli F, Prada A, et al. A phase I study of recombinant interleukin-2 in melanoma patients: toxicity and clinical effects. Tumori 1987; 73: 575.

    PubMed  CAS  Google Scholar 

  427. Marshall JS, and Bienenstock J. The role of mast cells in inflammatory reactions of the airways, skin and intestine. Curr Opin Immunol 1990; 6: 853.

    Google Scholar 

  428. Matsuda M, Motoji T, Oshimi K, Mizoguchi H. Effects of interleukin 7 on proliferation of hematopoietic malignant cells. Exp Hematol 1990; 18: 965–967.

    Google Scholar 

  429. Matsuda R, Takahashi T, Nakamura S, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993; 142: 339–349.

    PubMed  CAS  Google Scholar 

  430. Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment protects target cells from tumor and allospecific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994; 180: 2731.

    Google Scholar 

  431. Matsue H, Bergstresser PR, Takashima A. Keratinocyte derived IL-7 serves as a growth factor for dendritic epidermal T cells in mice. J Immunol 1993; 151: 6012–6019.

    PubMed  CAS  Google Scholar 

  432. Matsue H, Cruz PD, Bergstresser PR, Takashima A. Cytokine expression by epidermal subpopulations. J Invest Dermatol 1992; 99: 425.

    Google Scholar 

  433. Matsue H, Bergstresser PR, Takashima A. Reciprocal cytokine mediated cellular interactions in mouse epidermis: promotion of y5 T cell growth by IL-7 and TNFa and inhibition of keratinocyte growth by y interferon. J Invest Dermatol 1993b; 101: 543.

    PubMed  CAS  Google Scholar 

  434. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic nude mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002.

    PubMed  CAS  Google Scholar 

  435. Matsui Y, Zsebo KM, Hogan LM. Embryonic expression of hematopoietic growth factor encoded by SI locus and the ligand for c kit. Nature 1990; 343: 667–669.

    Google Scholar 

  436. Matsushima K, Oppenheimer JJ. Interleukin 8 and MCAF: Novel inflammatory cytokines inducible by IL-1 and TNF∝. Cytokine 1989; 1: 2–13.

    PubMed  CAS  Google Scholar 

  437. Mazumder A, Eberlein TJ, Grimm EA, et al. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 1984; 53: 896.

    PubMed  CAS  Google Scholar 

  438. Mayordoma JI, Zorina T, Storkus WJ, et al. Bone marrow derived dendritic cells pulded with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Mature Medicine 1995; 1: 1297–1302.

    Google Scholar 

  439. McBride WH, Thacker JD, Comora S, et al. Genetic modification of a murine fibrosarcoma to produce Interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res 1992; 52: 3931–3937.

    PubMed  CAS  Google Scholar 

  440. McCain RW, Dessypris EN, Christman JW. Granulocyte/ macrophage colony stimulating factor stimulates human polymorphonuclear leukocytes to produce interleukin 8 in vitro. J Respir Cell Mol Biol 1993; 8: 28.

    CAS  Google Scholar 

  441. Mcintosh JK, Mule JJ, Krosnick JA, Rosenberg SA. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2 and alpha-interferon and its synergistic antitumor effects in mice. Cancer Res 1991; 49: 1408.

    Google Scholar 

  442. Mcintosh JK, Mule J J, Merino MJ, Rosenberg SA. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. Cancer Res 1988; 48:4011.

    PubMed  CAS  Google Scholar 

  443. McKenzie ANJ, Culpepper JA, DeWaal Malefyt R, et al. Interleukin 13, a novel T cell derived cytokine that regulates human monocyte and B cell function. Proc Nat Acad Sci USA 1993; 90: 3735–3739.

    PubMed  CAS  Google Scholar 

  444. Mehrota PT, Wu D, Crim JA, et al. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 1993; 151: 2444–2452.

    Google Scholar 

  445. Mehrota PT, Grant AJG and Siegel JP. Synergistic effects of IL7 and ILl2 on Human T cell activation. J Immunol 1995; 154:5093–5102.

    Google Scholar 

  446. Melioli G, Sertoli MR, Bruzzone M, et al. A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: toxic effects and immunologic results. Am J Clin Oncol 1991; 14: 231–237.

    PubMed  CAS  Google Scholar 

  447. Merberg DM, Wolf SF, Clark SC. Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today 1992; 14:77.

    Google Scholar 

  448. Merchant RE, Merchant LH, Cook SHS, et al. Intralesional infusion of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of patients with malignant brain tumor. Neurosurgery 1988; 23: 725.

    PubMed  CAS  Google Scholar 

  449. Merluzzi VJ, Welte K, Mertelsmann R. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin-2. J Immunol 1983; 131:806.

    PubMed  CAS  Google Scholar 

  450. Mertelsmann R, Welte K, Sternberg C, et al. Treatment of immunodeficiency with interleukin-2: initial exploration. J Biol Response Modif 1984; 4:483.

    Google Scholar 

  451. Metcalf D. In vivo response to recombinant multi-CSF and GM-CSF (abstract). Biological Therapy of Cancer: A 1986 Update, Chapel-Hill, N.C.

    Google Scholar 

  452. Metcalf D. Control of granulocytes and macrophages: molecular, cellular and clinical aspects. Science 1991; 254: 529.

    PubMed  CAS  Google Scholar 

  453. Meyers F, Paradise C, Scudder S, et al. A phase I study including pharmacokinetics of pegylated interleukin 2 in patients with advanced cancer (Meeting Abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A274.

    Google Scholar 

  454. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481.

    PubMed  CAS  Google Scholar 

  455. Mier JW, Gallo RC. Isolation and purification of human Tcell growth factor. Proc Natl Acad Sci (USA) 1980; 77: 6134.

    CAS  Google Scholar 

  456. Mier JW, Aronson FR, Numerof RP, et al. Toxicity of immunotherapy with interleukin-2 and lymphokineactivated killer cells. Pathol Immunopathol Res 1988; 7: 459.

    PubMed  CAS  Google Scholar 

  457. Mier JW, Brandon EP, Libby P, et al. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. J Immunol 1989; 143: 2407.

    PubMed  CAS  Google Scholar 

  458. Mier JW, Vachino G, Van derMeer JWM, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8:426.

    PubMed  CAS  Google Scholar 

  459. Migliorati G, Pagilacci C, Moraca R, et al. Interleukins modulate glucocorticoid induced thymocyte apoptosis. Int J Clin Lab Res 1992; 21: 300–3.

    PubMed  CAS  Google Scholar 

  460. Miki S, Iwano Y, Miki Y, et al. Interleukin 6 functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett 1989; 250: 607–610.

    PubMed  CAS  Google Scholar 

  461. Mingari MC, Gerosa F, Carra G, et al. Human interleukin- 2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 1984; 312: 641.

    PubMed  CAS  Google Scholar 

  462. Minty A, Chalon P, Derocq JM, et al. Interleukin 13: A novel human lymphokine regulating inflammatory and immune responses Nature 1993; 362: 248–250.

    PubMed  CAS  Google Scholar 

  463. Mitchell LC, Davis LS, Lipsky PE. Promotion of human T lymphocyte proliferation by IL-4. J. Immunol 1989; 142: 1548–1557.

    PubMed  CAS  Google Scholar 

  464. Mitchell MS, Kempf RA, Harvel W, et al. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma. Bull NY Acad Med 1989; 65: 128.

    CAS  Google Scholar 

  465. Mittelman A, Huberman M, Fallon B, et al. Phase I study of recombinant interleukin 2 and recombinant human interferon alpha in patients with melanoma, renal cell carcinoma, colorectal cancer and malignant B-cell disease (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A696.

    Google Scholar 

  466. Mittelman A, Puccio C, Ahmed T, et al. A phase II trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma. Cancer 1991; 68: 1699–1702.

    PubMed  CAS  Google Scholar 

  467. Mizel SB, Dawyer JM, Krane SM, et al. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin-1). Proc Natl Acad Sci (USA) 1981; 78: 2474.

    CAS  Google Scholar 

  468. Mizel SB. The interleukins. FASEB J 1989; 3: 2379–2388.

    PubMed  CAS  Google Scholar 

  469. Mochizuki DY, Eisenman JR, Conlon PJ, et al. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc Natl Acad Sci (USA) 1987; 84:5267–5271.

    CAS  Google Scholar 

  470. Mohamadzadeh M, Takashima A, Dougherty I, et al. Ultraviolet B radiation up regulates the expression of IL- 15 in human skin. J Immunol 1995; 155:4492–4496.

    PubMed  CAS  Google Scholar 

  471. Moissec P, Yu CL, Ziff M. Lymphocyte chemotactic activity of interleukin 1 .J Immunol 1984; 133: 2007.

    Google Scholar 

  472. Moller A, Lippert U, Lessmann D, et al. Human mast cells produce IL8. J Immunol 1993; 151: 3261.

    PubMed  CAS  Google Scholar 

  473. Molmenti EP, Ziambaras T, Perlmutter DH. Evidence for an acute phase response in human intestinal epithelial cells .J Biol Chem 1993; 268: 12116–14124.

    Google Scholar 

  474. Monroe JG, Haldar S, Prystowsky MB, Lammie P. Lymphokine regulation of inflammatory process: IL4 stimulates fibroblast proliferation. Clin Immunol Immunopathol 1988; 49:292.

    PubMed  CAS  Google Scholar 

  475. Moore KW, Viera P, Fiorentino DF, et al. Homology of cytokine synthesis inhibitor factor (IL-10) to the Epstein Barr virus gene BCRFI. Science 1990; 248: 1230–1234.

    PubMed  CAS  Google Scholar 

  476. Moore MAS, Warren DJ. Synergy of interleukin-1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci (USA) 1987; 84: 7134–7138.

    CAS  Google Scholar 

  477. Morel F, Delwail V Brizard A, et al. Effects of sCD23 on proliferation of leukemic cells from a patient with chronic myelogenous leukemia during blast crisis. Amer J Hematology 1993; 44 :60–62.

    CAS  Google Scholar 

  478. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 1976; 193: 1007.

    PubMed  CAS  Google Scholar 

  479. Morisaki T, Morton DL, Uchiyama A, et al. Characterization and augmentation of CD4+ cytotoxic T cell lines against melanomas. Cancer Immunol Immunother 1994; 39: 172–178.

    PubMed  CAS  Google Scholar 

  480. Morisaki T, Uchiyama A, Yuzuki D, et al. Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells. Cancer Res 1994; 54: 1113–8.

    PubMed  CAS  Google Scholar 

  481. Morisaki T, Yuzuki D, Lin R, et al. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin-4. Cancer Res. 1992; 52: 6059–6065.

    PubMed  CAS  Google Scholar 

  482. Morris SC, Madden KB, Adamovicz JJ, et al. Effects of ILl2 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 1994; 152: 1047–1056.

    PubMed  CAS  Google Scholar 

  483. Morrissey PJ, Goodwin RG, Nordan RP, et al. Recombinant interleukin 7, pre-B cell growth factor has costimulatory activity on purified mature T cells. J Exp Med 1989; 169: 707–716.

    PubMed  CAS  Google Scholar 

  484. Mosley B, Beckman MP, March CJ, et al. The murine interleukin-4 receptor: molecular cloning and characterization of the secreted and membrane bound forms. Cell 1989; 59:355.

    Google Scholar 

  485. Moser B, Schumacher C, vonTscharner V, et al. Neutrophil activating peptide 2 and melanoma growth stimulatory activity interact with neutrophil activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem 1991; 266: 10667.

    Google Scholar 

  486. Mosmann TR. Cytokine secretion patterns and cross regulation of T cell subsets. Immunol Res 1991; 10: 183–188.

    PubMed  CAS  Google Scholar 

  487. Mosmann T, Bond M, Coffman R, et al. T cell and mast cell lines respond to B cell stimulatory factor 1. Proc Nat Acad Sci USA 1986; 83: 1857.

    Google Scholar 

  488. Mosmann T, Cherwinski H, Bond M, et al. Two types of murine helper T cell clones. 1. Definition to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348.

    PubMed  CAS  Google Scholar 

  489. Motro B, Itin A, Sachs L, et al. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990; 87: 3092–3096.

    PubMed  CAS  Google Scholar 

  490. Muegge K, Vial MP, Durum SK. Interleukin 7: a cofactor for V(D)J rearrangement of the T cell receptor beta gene. Science 1993; 261: 93–5.

    PubMed  CAS  Google Scholar 

  491. Mukaida N, Harada A, Yasumoto K et al. Properties of proinflammatory cell type specific leukocyte chemotactic cytokines interleukin 8 (IL8) and monocyte chemotactic and activating factor (MCAF). Microbiol Immunol 1992; 36: 773–789.

    PubMed  CAS  Google Scholar 

  492. Mule JJ, Shu S, Rosenberg SA. The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 1985; 135: 646.

    PubMed  CAS  Google Scholar 

  493. Mule JJ, Shu S, Schwarz SL, et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487.

    PubMed  CAS  Google Scholar 

  494. Mule JJ, Smith CA, Rosenberg SA. Interleukin-4 (B cell stimulatory factor) can mediate the induction of lymphokine activated killer cell activity directed against fresh tumor cells. J Exp Med 1987; 166: 792–7.

    PubMed  CAS  Google Scholar 

  495. Mule JJ, Custer MC, Travis WD, et al. Cellular mechanisms of the antitumor activity of recombinant IL-6 inmic q. J Immunol 1992; 148: 2622–2629.

    PubMed  CAS  Google Scholar 

  496. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167: 332.

    PubMed  CAS  Google Scholar 

  497. Murphy EE, Terres G, Macatonia SE, et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994; 180: 223–231.

    PubMed  CAS  Google Scholar 

  498. Murphy WJ, Back TC, Conlon KC, et al. Antitumor effects of interleukin 7 and adoptive immunotherapy on human colon carcinoma xenografts. J Clinical Invest 1993;92:1918–1924.

    CAS  Google Scholar 

  499. Murphy P, Tiffany H. Cloning of complimentary DNA encoding a functional human IL-8 receptor. Science 1991; 253: 1280.

    PubMed  CAS  Google Scholar 

  500. Musashi M, Yang Y-C, Paul SR, et al. Direct and synergistic effects of interleukin 11 on murine hematopoiesis in culture Proc Nat Acad Sci USA 1991; 88: 765–769.

    PubMed  CAS  Google Scholar 

  501. Nakamura S, Nakata K, Kashimoti S, et al. Anti-tumor effect of recombinant human interleukin-1 alpha against murine syngeneic tumors. Jpn J Cancer Res 1986; 77: 767–773.

    PubMed  CAS  Google Scholar 

  502. Nakamura S, Kashimoto S, Kajikawa F, Nakata K. Combination effect on recombinant interleukin l a with antitumor drugs on syngeneic tumors in mice. Cancer Res 1991;51:215–221.

    PubMed  CAS  Google Scholar 

  503. Nakanishi K, Malek TR, Smith KA, et al. Both interleukin 2 and a second T cell derived factor in EL-4 supernatant have activity as differentiation factors in IgM synthesis. J Exp Med 1984; 160: 1605.

    PubMed  CAS  Google Scholar 

  504. Namen AE, Schierer AE, March CJ, et al. B cell precursorgrowth promoting activity and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988; 167:988–1002.

    PubMed  CAS  Google Scholar 

  505. Namen AS, Lupton S, Hjerrild K, et al. Stimulation of B cell progenitors by cloned murine IL-7. Nature 1988; 333: 571.

    PubMed  CAS  Google Scholar 

  506. Nastala CL, Edington HD, McKinney TG, et al. Recombinant ILl2 administration induced tumor regression in association with IFN-production. J Immunol 1994; 153: 1697–1706.

    PubMed  CAS  Google Scholar 

  507. Natali PG, Nicotra MR, Sures I, et al. Breast cancer is associated with loss of c-kit oncogene product. Int J Cancer 1992a; 52:713–717.

    PubMed  CAS  Google Scholar 

  508. Natali PG, Nicotra MR, Sures I, et al. Expression of c kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992b; 52: 6139–6143.

    PubMed  CAS  Google Scholar 

  509. Natali PG, Nicotra MR, Winkler AB, et al. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto oncogene receptor. Int J Cancer 1992; 52: 197–201.

    PubMed  CAS  Google Scholar 

  510. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of Interferon y as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Me d 1983; 158: 670.

    CAS  Google Scholar 

  511. Naume B, Espevik T, Sundan A. Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+natural killer cells stimulated with interleukin 2 interleukin 7 and interleukin 12. Eur J Immunol 1993b; 23: 1831–8.

    PubMed  CAS  Google Scholar 

  512. Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor), IL-2, and IL-7 induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 1992; 148: 2429–2436.

    PubMed  CAS  Google Scholar 

  513. Naume B, Gately MK, Desai BB, et al. Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine 1993; 5: 38–46.

    PubMed  CAS  Google Scholar 

  514. Nawroth P, Handley D, Matsueda G, et al. Tumor necrosis factor/cachechtin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 1988; 168: 637–647.

    PubMed  CAS  Google Scholar 

  515. Neta R, Oppenheim JJ. Why should internists be interested in interleukin-1? Ann Intern Med 1988; 109: 1–3.

    PubMed  CAS  Google Scholar 

  516. Neta R, Oppenheim JJ. Cytokines in therapy of radiation injury. Blood 1988; 72: 1093–1095.

    PubMed  CAS  Google Scholar 

  517. Neta R, Douches SD, Oppenheim JJ. Interleukin-1 is a radioprotector. J Immunol 1986; 136: 2483–2488.

    PubMed  CAS  Google Scholar 

  518. Nicholls SE, Heyworth CM, Dexter TM, et al. IL-4 promotes macrophage development by rapidly stimulating lineage restriction of bipotent granulocyte macrophage colony forming cells. J Immunol 1995; 155: 845–853.

    PubMed  CAS  Google Scholar 

  519. Nishimura T, Uchiyama Y, Yagi H, Hashimoto Y. Administration of slowly released recombinant interleukin 2. J Immunol Methods 1986; 91: 21.

    PubMed  CAS  Google Scholar 

  520. Noelle R, Krammer P, Ohara J, et al. Increased expression of la antigens on resting B cells. A new role for B cell growth factor 1. Proc Nat Acad Sci USA 1984; 81: 6149.

    PubMed  CAS  Google Scholar 

  521. Noguchi M, Nakamura Y, Russel SM, et al. Interleukin receptor gamma chain a functional component of the interleukin 7 receptor. Science 1993; 262: 1877–1880.

    PubMed  CAS  Google Scholar 

  522. Nonaka M, Nonaka R, Wooley K, et al. Distinct immunohistochemical localization of IL-1 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995; 155: 3234–3244.

    PubMed  CAS  Google Scholar 

  523. Nophar Y, Kemper O, Brakebusch C, et al. Soluble forms of tumor necrosis factor receptors (TNF-R’s). The cDNA for the type I TNF-R cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269–3278.

    PubMed  CAS  Google Scholar 

  524. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982;55: 1063.

    Google Scholar 

  525. Obiri N, Hillman GG, Haas GP, et al. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor growth in vitro by interleukin-4. J Clin Investigation 1993; 91: 88–93.

    CAS  Google Scholar 

  526. O’Garra A, Chang R, Hatings R, et al. Ly IB (B-l) cells are the main source of B-cell derived IL-10. Eur J Immunol 1992; 22: 711.

    PubMed  Google Scholar 

  527. Ogasawa M, Rosenberg S. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with y interferon genes. Cancer Res 1993; 53:3561–3568.

    Google Scholar 

  528. Ogawa N, Itoh M, Gately Y. Abnormal production of B cell growth factor in patients with systemic lupus erythmatosis. Clin Exp Immunol 1992; 89: 26–38.

    PubMed  CAS  Google Scholar 

  529. Ognibene FP, Rosenberg SA, Lotze M, et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 1988; 94: 750.

    PubMed  CAS  Google Scholar 

  530. Ohara J, Paul WE. Upregulation of the interleukin 4/B cell stimulatory factor receptor expression. Proc Nat Acad Sci USA 1988; 85: 8221.

    PubMed  CAS  Google Scholar 

  531. Okahara H, Yagita H, Miyake K, Okumura K. Involvement of very late activation antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in tumor necrosis factor a enhancement of experimental metastasis. Cancer Res 1994: 54; 3233–3236.

    PubMed  CAS  Google Scholar 

  532. Okayashiki K, Miyauchi J, Ohyashiki JH, et al. Interleukin 7 enhances colony growth and induces CD 20 antigen of a Ph+ acute lymphoblastic leukemia cell line. Leukemia 1993; 7: 1034–40.

    Google Scholar 

  533. Okazaki H, Ito M, Sudo T, et al. IL-7 promotes thymocytes bearing αβ or γδ T cell receptors in vitro: Synergism with IL-2. J Immunol 1989; 143: 2917–2922.

    PubMed  CAS  Google Scholar 

  534. Oldham RK. Biological approaches to cancer therapy. 1st Italian/American Symposium on Immunobiologic Aspects in Oncology, New York City, September 1990.

    Google Scholar 

  535. Oldham RK, Blumenschein G, Schwartzberg L, et al. Combination biotherapy utilizing interleukin-2 and alphainterferon in patients with advanced cancer: An NBSG trial. Mol Biother 1992; 4: 4–9.

    PubMed  CAS  Google Scholar 

  536. Oldham RK. Cancer cures: by the people, for the people, at what cost? Mol Biother 1990; 2(1) 2–3.

    PubMed  CAS  Google Scholar 

  537. Oldham RK. Cancer and diabetes: are there similarities? Mol Biother 1990; 2(3) 130–131.

    PubMed  CAS  Google Scholar 

  538. Oldham RK, Stark J, Barth NM, et al. Continuous infusion interleukin-2 and cyclophosphamide as treatment of advanced cancer: An NBSG trial. J Natl Cancer Inst 1990.

    Google Scholar 

  539. Oldham RK, Thurman GB. Effects of cytokines on recovery from radiation exposure. In: Rotman M, Rosenthal CJ, eds. Medical radiology - Diagnostic imaging and radiation oncology. Concomitant continuous infusion chemotherapy and radiation. Springer-Verlag, New York, 1990.

    Google Scholar 

  540. Oldham RK, Dillman RO, Yannelli JR, et al. Continuous infusion interleukin-2 and tumor derived activated cells as treatment of advanced solid tumors: an NBSG trial. Mol Biother 1991; 3(2) 68–73.

    PubMed  CAS  Google Scholar 

  541. Oldham RK. Therapy with tumor derived activated lymphocytes. In: Tumor Immunology. Goldfarb R and Whiteside T, eds. Marcel Dekker, New York, pp. 251–271, 1992.

    Google Scholar 

  542. Oldham RK, Blumenschein G, Schwartzberg L, et al. Combination biotherapy utilizing interleukin-2 and alphainterferon in patients with advanced cancer, an NBSG trial. Mol Biother 1992; 4: 4–9.

    PubMed  CAS  Google Scholar 

  543. Oldham RK, Lewko W, Good R, et al. Growth of tumor derived activated T-cells for the treatment of cancer. Cancer Biotherapy 1994; 9(3) 211–224.

    PubMed  Google Scholar 

  544. Oldham RK, Lewko WM, Good RW, Sharp E. Cancer biotherapy with interferon, interleukin 2 and tumor derived activated cells (TDAC). In Vivo 1994; 8: 653–664.

    PubMed  CAS  Google Scholar 

  545. Oldham RK and Lewko WM. Personal Communication.

    Google Scholar 

  546. Oliver RTD, Crosby D, Nouri A, et al. Evaluation of the effect of continuous infusion recombinant interleukin-2 on peripheral blood leucocytes of patients with terminal malignancy. Br J Cancer 1989; 60: 934.

    PubMed  CAS  Google Scholar 

  547. O’Neal KD, and Yu-Lee L. The proline rich motif (PRM): a novel feature of the cytokine/hematopoietin receptor superfamily. Lymphokine Cytokine Res. 1993; 12: 309–312.

    PubMed  Google Scholar 

  548. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 3962–3968.

    PubMed  CAS  Google Scholar 

  549. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. There is more than one interleukin-1. Immunol Today 1986;7:45–56.

    CAS  Google Scholar 

  550. Orange JS, Wolf SF, Biron CR. Effects of ILl2 on the response and susceptibility to experimental viral infections. J Immunol 1993; 152: 1253.

    Google Scholar 

  551. Ortaldo JR, Mason AT, Gerard JP, et al. Effects of natural and recombinant IL2 on regulation of IFN gamma production and natural killer activity: lack of involvement of Tac antigen for these immunoregulatory effects. J Immunol 1984; 133:779.

    PubMed  CAS  Google Scholar 

  552. Ortaldo JR, Mason A, Overton R. Lymphokine-activated killer cells. Analysis of the progenitors and effectors. J Exp Med 1986; 164: 1193.

    PubMed  CAS  Google Scholar 

  553. Oshimi K, Oshimi Y, Akutsu M, et al. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938.

    PubMed  CAS  Google Scholar 

  554. Ostensen ME, Thiele DL, and Lipsky PE. Tumor necrosis factor enhances cytolytic activity of human natural killer cells. J Immunol 1987; 138:4185.

    PubMed  CAS  Google Scholar 

  555. Owen-Schaub LB, Gutterman JU, Grimm EA. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor and Interleukin 2 in the generation of human lymphokine activated killer cell cytotoxicity. Cancer Res 1988;48:788–792.

    PubMed  CAS  Google Scholar 

  556. Paciucci PA, Holland JF, Glidwell O, et al. Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2 activated cells in patients with advanced cancer. J Clin Oncol 1989; 1989: 869.

    Google Scholar 

  557. Page TH, Willcocks JL, Taylor-Fishwick DA, Foxwell BMJ. Characterization of a novel high affinity human IL- 7 receptor. Expression on T cells and association with IL- 7 driven proliferation. J Immunol 1993; 151: 4753–4763.

    PubMed  CAS  Google Scholar 

  558. Paige CJ, Figarella EF, Cuttito M, et al. Natural cytotoxic cells against solid tumors in mice: II. Some characteristics of the effector cells. J Immunol 1978; 121: 1827.

    PubMed  CAS  Google Scholar 

  559. Pandrau D, Frances V, Martinez Valdez H, et al. Characterization of a t(l; 19) pre-B acute lymphoblastic leukemia (ALL) cell line which proliferates in response to IL-7. Leukemia 1993;7:635–42.

    PubMed  CAS  Google Scholar 

  560. Paolozzi F, Zamkoff K, Doyle M, et al. Phase I trial of recombinant interleukin-2 and recombinant B-interferon in refractory neoplastic diseases. J Biol Response Modif 1989; 8: 122.

    CAS  Google Scholar 

  561. Papa MZ, Yang JC, Vetto JT, et al. Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 1988; 48: 122.

    PubMed  CAS  Google Scholar 

  562. Park LS, Friend DJ, Schmierer AE, et al. Murine interleukin 7 (IL-7) receptor. Characterization on an IL7 dependent cell line. J Exp Med 1990; 171: 1073.

    PubMed  CAS  Google Scholar 

  563. Park LS, Friend D, Sassenfeld HM, Urdal DL. Characterization of human B cell stimulatory factor 1 receptor. J Exp Med 1987; 166:476–488.

    PubMed  CAS  Google Scholar 

  564. Pauker K, Cantrell K, Henle W. Quantitative studies on viral interference in suspended L cells. III. Effects of interfering viruses and interferon on growth rate of cells. Virology 1962; 17: 324–334.

    Google Scholar 

  565. Paul NL, Ruddle NH. Lymphotoxin. Ann Rev Immunol 1986;6:407–438.

    Google Scholar 

  566. Paul SR, Bennett F, Calvetti JA, et al. Molecular cloning of a cDNA encoding interleukin 11, a novel stromal cell derived lymphopoietic and hematopoietic cytokine. Proc Nat Acad Sci USA 1990; 87: 7512.

    PubMed  CAS  Google Scholar 

  567. Paul WE, Ohara J. B-cell stimulatory factor-1/interleukin 4 .Annu Rev Immunol 1987; 5: 429,460.

    Google Scholar 

  568. Peace DJ, Cheever MA. Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 1989; 169: 161.

    PubMed  CAS  Google Scholar 

  569. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724.

    PubMed  CAS  Google Scholar 

  570. Perussia B, Ramoni C, Anegon I, et al. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid lines. Natlmmun Cell Growth Regul 1987; 6: 171.

    CAS  Google Scholar 

  571. Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Ann Rev Biochem 1987; 56: 727–777.

    PubMed  CAS  Google Scholar 

  572. Peveri P, Walz A, Dewald B, Baggiolini M. A neutrophil activating factor produced by human mononuclear phagocytes. J Exp Med 1988; 167: 1547.

    PubMed  CAS  Google Scholar 

  573. Phillips JH, Lanier LL. Dissection of the lymphokineactivated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814.

    PubMed  CAS  Google Scholar 

  574. Pippin BA, Rosenstein M, Jacob WF, et al. Local IL-4 delivery enhances immune reactivity to murine tumors: Gene therapy in combination with IL2. Cancer Gene Therapy 1994; 1:35–42.

    PubMed  CAS  Google Scholar 

  575. Pisa P, Halapi E, Pisa EK, et al. Selective expression of interleukin 10, interferon y, and granulocyte macrophage colony stimulating factor in ovarian cancer biopsies. Proc Nat Acad Sci 1992; 89: 7708.

    PubMed  CAS  Google Scholar 

  576. Pizza G, Severini G, Menniti D, et al. Tumour regression after intralesional injection of interleukin 2 in bladder cancer. Preliminary report. Int J Cancer 1984; 34: 359.

    PubMed  CAS  Google Scholar 

  577. Pizza G, Viza D, DeVinci C, et al. Intralymphatic administration of interleukin-2 in cancer patients: a pilot study. Lymphokine Res 1988; 7:45.

    PubMed  CAS  Google Scholar 

  578. Plate JMD, Knospe WH, Harris JE, Gregory SA. Normal and aberrant expression of cytokines in neoplastic cells from lymphocytic leukemias. Human Immunol 1993; 36: 249–258.

    CAS  Google Scholar 

  579. Plum J, DeSmedt M, Leclerq G. Exogenous IL-7 promotes the growth of CD33-CD4-CD8-CD44+CD25+/- precursor cells and blocks the differentiation pathway of TCR-alpha beta cells in fetal thymus organ culture. J Immunol 1993; 150: 2706–2716.

    PubMed  CAS  Google Scholar 

  580. Pugin J, Schurer-Maley C-C, Leturcq D, et al. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide binding protein and soluble CD 14. Proc Nat Acad Sci USA 1993; 90:2744.

    PubMed  CAS  Google Scholar 

  581. Pulaski B, Maltby K, Sastri N, et al. IL-3 enhances presentation of exogenous tumor antigen with class I by a rare subpopulation of host macrophages. Proc AACR 1995; 36:474#2826.

    Google Scholar 

  582. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4 independent IgG4 and IgE synthesis and CD 23 expression by B cells. Proc Nat Acad Sci USA 1993; 90: 3730–3735.

    PubMed  CAS  Google Scholar 

  583. Puri R, Travis W, Rosenberg S. Decrease in interleukin-2- induced vascular leakage in the lungs of mice by administration of recombinant interleukin-1 alpha in vivo. Cancer Res 1989 49: 969.

    PubMed  CAS  Google Scholar 

  584. Puri RK, Ogata M, Leland GM, et al. Expression of high affinity Interleukin 4 receptors on murine sarcoma cells and receptor mediated cytotoxicity of tumor cells to chimeric protein between Interleukin 4 and pseudomonas exotoxin. Cancer Res 1991; 51: 3011–3017.

    PubMed  CAS  Google Scholar 

  585. Qi J, Kreutzer DL. Fibrin activation of vascular endothelial cells. Induction of IL-8 secretion. J Immunol 1995; 155:867–876.

    PubMed  CAS  Google Scholar 

  586. Rabin EM, Ohara J, and Paul WE. B cell stimulatory factor 1 activates resting B cells. Proc Nat Acad Sci USA 1985;82:2935–2939.

    PubMed  CAS  Google Scholar 

  587. Redman BG, Abubakr Y, Chou T, et al. Phase II trial of recombinant interleukin-1(3 in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 1994; 13: 255.

    Google Scholar 

  588. Reed JC, Abidi AH, Alpers JD, et al. Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression. J Immunol 1986; 137: 150.

    PubMed  CAS  Google Scholar 

  589. Reittie JE, Hoffbrand AV Interleukin-4 (IL-4) inhibits proliferation and spontaneous cytokine release by chronic lymphocytic leukemia cells. Leukemia Res 1994; 18: 55–60.

    CAS  Google Scholar 

  590. Renauld JC, Druez C, Kermouni A, et al. Expression cloning of murine and human Interleukin 9 receptor DNAs. Proc Nat Acad Sci USA 1992; 89: 5690–5694.

    PubMed  CAS  Google Scholar 

  591. Renauld JC, Houssiau F, Louahed J, et al. Interleukin 9 Int Rev Exp Pathol 1993; 34: 99–109.

    PubMed  Google Scholar 

  592. Rennick D, Yang G, Muler-Sieburg C, et al. Interleukin 4 (B cell stimulatory factor 1) can enhance or antagonize the factor dependent growth of hematopoietic progenitor cells. Proc Nat Acad Sci USA 1987; 84: 6889.

    PubMed  CAS  Google Scholar 

  593. Renz H, Domenico J, Gelfand EW. IL-4 dependent upregulation of IL-4 receptor expression in murine T and B cells. J Immunol 1991; 146: 3049.

    PubMed  CAS  Google Scholar 

  594. Restifo NP, Speis PJ, Karp SE, et al. Non-immunogenic sarcoma transduced with the cDNA for interferon y elicits CD8+T cells against the wild type tumor: correlation with antigen presentation capability. J Exp Med 1992; 175: 1423–1431.

    PubMed  CAS  Google Scholar 

  595. Rice A, Kerr IM. Interferon mediated double stranded RNA dependent protein kinase is inhibited in extracts from vaccinia infected cells. J Virol 1984; 50: 229–236.

    PubMed  CAS  Google Scholar 

  596. Rich BE, Campos-Torres J, Tepper RI, et al. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993; 177: 305–316.

    PubMed  CAS  Google Scholar 

  597. Richards J, Mehta N, Schroeder L, Dordal A. Sequential chemotherapy/immunotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 1992; 11: 1189.

    Google Scholar 

  598. Richards JM, Vogelzang NJ, Ramming K, et al. Preliminary results of a randomized trial of recombinant human interleukin-2 given by continuous venous infusion with or without lymphokine activated killer cells (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1988; 7: A618.

    Google Scholar 

  599. Richter G, Kruger-Krasagakes S, Hein G, et al. Interleukin 10 transfected into Chinese Hamster Ovary Cells Prevents Tumor Growth and Macrophage Infiltration. Cancer Res 1993; 53:4134–4137.

    PubMed  CAS  Google Scholar 

  600. Riddell S, Cheever MA, Greenberg PD. Interleukin-2 in cancer immunotherapy. ISIAtlas Sci Immunol 1988; 175.

    Google Scholar 

  601. Rixe O, Benhammouda A, Antoine E, et al. Final results of a prospective multicentric study on 91 metastatic malignant melanoma (MMM) patients treated by chemoimmunotherapy (CH-IM) with cisplatin interleukin (IL-2) interferon-a (IFN). Proc Am Soc Clin Oncol 1994; 13: 399.

    Google Scholar 

  602. Robb RJ, Smith KA. Heterogeneity of human T-cell growth factors due to variable glycosylation. Mol Immunol 1981; 18: 1087.

    PubMed  CAS  Google Scholar 

  603. Robb RJ. Human T-cell growth factor: purification and interaction with a cellular receptor. Lymphokine Res 1982; 1:37.

    PubMed  CAS  Google Scholar 

  604. Robertson MJ, Soiffer RJ, Wolf SF, et al. Response of human natural killer cells to natural killer cell stimulatory factor: Cytolytic activity and proliferation of NK differentially regulated by NKSF.J Exp Med 1992; 175: 779–788.

    PubMed  CAS  Google Scholar 

  605. Romagnani S. Human TH1 and TH2 subset: Regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunopathology Int Arch Allergy Immunol 1992; 98: 279–285.

    CAS  Google Scholar 

  606. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412.

    PubMed  CAS  Google Scholar 

  607. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine- activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485.

    PubMed  CAS  Google Scholar 

  608. Rosenberg SA, Mule JJ, Speiss PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of highdose recombinant interleukin 2. J Exp Med 1985; 161: 1169.

    PubMed  CAS  Google Scholar 

  609. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889.

    PubMed  CAS  Google Scholar 

  610. Rosenberg SA, Spiess P, LaFreniere R. A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes. Science 1986; 233: 1318.

    PubMed  CAS  Google Scholar 

  611. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676.

    PubMed  CAS  Google Scholar 

  612. Rosenberg SA. Immunotherapy of patients with advanced cancer using recombinant lymphokines. Clin Courier 1989; 7: 16.

    Google Scholar 

  613. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863–1874.

    PubMed  CAS  Google Scholar 

  614. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474–485.

    PubMed  CAS  Google Scholar 

  615. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180–199.

    PubMed  CAS  Google Scholar 

  616. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622–632.

    PubMed  CAS  Google Scholar 

  617. Rosenberg SA, Yang JC, Topalian SL, et al. The treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271:907–913.

    PubMed  CAS  Google Scholar 

  618. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735.

    PubMed  CAS  Google Scholar 

  619. Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphocyte-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 1984; 44: 1946.

    PubMed  CAS  Google Scholar 

  620. Rosenthal NS, Hank JA, Kohler PC, et al. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2. J Biol Response Modif 1988; 7: 123.

    CAS  Google Scholar 

  621. Rossio JL, Thurman GB, Long C, et al. The BRMP IL-2 Reference Reagent. Lymphokine Res 1986; 5(SI): SI3.

    Google Scholar 

  622. Rousset, F, Garcia E, Peronne C, et al. Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Nat Acad Sci USA 1992; 89: 1890.

    PubMed  CAS  Google Scholar 

  623. Ruddle NH, Waksman BH. Cytotoxic effect of lymphocyte- antigen interaction in delayed hypersensitivity. Science 1967; 157: 1060–1062.

    PubMed  CAS  Google Scholar 

  624. Ruggiero V, Latham K, Baglioni C. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol 1987; 138:2711.

    PubMed  CAS  Google Scholar 

  625. Ruscetti FW, Morgan DA, Gallo RG. Selective in vitro growth of T-lymphocytes from normal bone marrows. Science 1976; 193: 1007–1008.

    PubMed  Google Scholar 

  626. Ruscetti FW, Morgan DA, Gallo RC. Functional and Morphologic Characterization of T cells continuously grown in vitro J Immunol 1977; 119: 131–138.

    PubMed  CAS  Google Scholar 

  627. Russell SM, Johnson JA, Noguchi M, et al. Interaction of IL-2R and c chains with Jakl and Jak3: Implications for XSCID and XCID. Science 1994; 266: 1042–1044.

    PubMed  CAS  Google Scholar 

  628. Rygard K, Nakamura T, Spang-THompsen M. Expression of the protoconcogene cmet and c kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts. British J Cancer 1993;67:37–46.

    Google Scholar 

  629. Sabelko K, Blumenthal D, Ford R, Ambrus J. ILl4 producing and responsive cells are found in germinal centers. FASEB J 1994; 8: A999.

    Google Scholar 

  630. Sakata T, Iwagami S, Tsurata Y, et al. Constitutive expression of interleukin 7 mRNA and production of IL-7 by a cloned murine thymic stromal cell line. J Leukocyte Biol 1990; 144:3015.

    Google Scholar 

  631. Sanderson CJ, Campbell HD, Young IG. Molecular and cellular biology of eosinophil differentiation factor (interleukin 5) and its effects on human and mouse B cells. Immunol Rev 1988; 109: 29–50.

    Google Scholar 

  632. Sato TA, Widmer MB, Finkelman FD, et al. Recombinant soluble murine IL-4 receptor can inhibit of enhance IgE responses in vivo. J Immunol 1991; 150: 2717.

    Google Scholar 

  633. Sauder DN, Mounessa NL, Katz SI, et al. Chemotactic cytokines: the role of leukocyte pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol 1984; 132: 828.

    PubMed  CAS  Google Scholar 

  634. Scala G, Kuang YD, Hall RE, et al. Accessory cell function of human B cells. I. Production of both interleukin-1 like activity and interleukin-1 inhibitory factor by an EBV-transformed B cell line. J Exp Med 1984; 159: 1637.

    PubMed  CAS  Google Scholar 

  635. Schadendorf D, Bohm M, Moller P, Grunewald T, Czarnetzki BM. Interleukin 7 induces differential lymphokine- activated killer cell activity against human melanoma cell, keratinocytes and endothelial cells. J Invest Dermatol 1994; 102: 838–842.

    PubMed  CAS  Google Scholar 

  636. Schadendorf D, Moller A, Algermissen B, et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 15: 2667–2675.

    Google Scholar 

  637. Schendel DJ, Gansbacher B. Tumor specific lysis of Human renal cell carcinomas by tumor infiltrating lymphocytes: Modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous interferon treatment. Cancer Res 1993; 4020-4025.

    Google Scholar 

  638. Schiller JH, Hank J, Storer B, et al. A direct comparison of immunological and clinical effects of interleukin-2 with and without interferon-a in humans. Cancer Res 1993; 53: 1286–1992.

    PubMed  CAS  Google Scholar 

  639. Schmidt JA, Mizel SB, Cohen D, et al. Interleukin-1: a potential regulator of fibroblast proliferation. J Immunol 1982; 128:2177.

    PubMed  CAS  Google Scholar 

  640. Schraufstatter IU, Barritt DS, Ma M, et al. Multiple sites on IL-8 responsible for binding to a and (3 IL-8 receptors. J Immunol 1993; 151: 6418–6428.

    PubMed  CAS  Google Scholar 

  641. Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin 6 production as a common feature. Int J Cancer 1992; 51: 296–301.

    PubMed  CAS  Google Scholar 

  642. Schroder J, Mrowietz U, Morita E, Christophers E. Purification and partial biochemical characterization of a human monocyte-derived neutrophil activating peptide that lacks interleukin 1 activity. J Immunol 1987; 139: 3474.

    PubMed  CAS  Google Scholar 

  643. Schroder JM, Christophers E. Secretion of novel and homogeneous neutrophil activating peptides by LPS stimulated human endothelial cells. J Immunol 1989; 142: 244.

    PubMed  CAS  Google Scholar 

  644. Schuchter L, Neuberg D, Atkins M, et al. A phase I study of interleukin-1 alpha (IL-1) and high dose cyclophosphamide (Cy) in patients with advanced cancer. Proc Am Soc Clin Oncol 1994; 13: 133.

    Google Scholar 

  645. Schuerer-Maly CC, Eckmann L, Kagoff MF, et al. Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology 1994; 81: 85–91.

    PubMed  CAS  Google Scholar 

  646. Schultz KR, Klarnet JP, Peace DJ, et al. Adoptive transfer of lymphokine-activated killer (LAK) cells augments monoclonal antibody eradication of murine lymphoma without toxicity (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1989; 30: A1441.

    Google Scholar 

  647. Schwalb DM, Han H-M, Marino M, et al. Identification of a new receptor subtype for tumor necrosis factor a. J Biol Chem 1993; 268: 9949–9954.

    PubMed  CAS  Google Scholar 

  648. Schwartzberg L, Tauer K, Birch R, et al. Phase I study of sequential recombinant tumor necrosis factor (rTNF) and recombinant interleukin-2 (rIL-2) in patients with advanced malignancy (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A711.

    Google Scholar 

  649. Schweizer RC, Welmers BAC, Raaijmakers JAM, et al. RANTES and Interleukin 8 induced responses in normal human eosinophils: effects of priming with IL5. Blood 1994; 83:3697.

    PubMed  CAS  Google Scholar 

  650. Sebok K, Woodside D, al-Aoukaty A. IL-8 induces the locomotion on human IL 2 activated natural killer cells. Involvement of a guanine nucleotide binding protein. J Immunol 1993; 150: 1524–1534.

    PubMed  CAS  Google Scholar 

  651. Sehmi R, Cromwell O, Wardlaw AJ, et al. Interleukin 8 is a chemoattractant for eosinophils purified from subjects with blood eosinophilia but not from normal healthy subjects. Clin Exp Allergy 1993; 23: 1027.

    PubMed  CAS  Google Scholar 

  652. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991; 51: 2416–2419.

    PubMed  CAS  Google Scholar 

  653. Shaw J, Caplan B, Paetkau V, et al. Cellular origins of costimulator (IL-2) and its activity in cytotoxic Tlymphocyte responses. J Immunol 1980; 124: 2231.

    PubMed  CAS  Google Scholar 

  654. Shaw J, Monticone V, Paetkau V Partial purification and molecular characterization of a lymphokine (co-stimulator) required for the mitogenic response of mouse thymocytes in vitro. J Immunol 1978; 120: 1967.

    PubMed  CAS  Google Scholar 

  655. Shiloni E, Eisenthal A, Sachs D, Rosenberg SA. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol1987 138: 1992.

    PubMed  CAS  Google Scholar 

  656. Sica D, Rayman P, Edinger M, et al. Interleukin 7 enhances the proliferation and effector function of tumor infiltrating lymphocytes from renal cell carcinoma. International J Cancer 1993; 53: 941–947.

    CAS  Google Scholar 

  657. Sideras P, Palacios R. Bone marrow pre-T and pre-B lymphocyte clones express functional receptors for interleukin (IL)-3 and interleukin 4/BSF-l and non-functional receptors for IL2. Eur J Immunol 1987; 17: 217.

    PubMed  CAS  Google Scholar 

  658. Siebruth D, Jabs EW, Warrington JA, et al. Assignment of NKSF/IL-12, a unique cytokine composed of two unrelated subunits to chromosomes 3 and 5. Genomics 1992; 14:59–62.

    Google Scholar 

  659. Siegel JP, Sharon M, Smith PL, Leonard WJ. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 1987; 238: 75.

    PubMed  CAS  Google Scholar 

  660. Silagi S, Schaefer AE. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide. J Biol Response Modif 1986; 5:411.

    CAS  Google Scholar 

  661. Silvani A, Ferrari G, Paonessa G, et al. Down regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. Cancer Res 1995; 55:2200–2205.

    PubMed  CAS  Google Scholar 

  662. Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54: 3232–3247.

    Google Scholar 

  663. Smith JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 10: 1141–1152.

    PubMed  Google Scholar 

  664. Smith KA. Interleukin-2: Inception, impact and implications. Science 1988; 240: 1169–1176.

    PubMed  CAS  Google Scholar 

  665. Smyth MJ, Ortaldo JR. Comparison of the effect of IL2 and IL6 on the lytic activity of purified human peripheral blood large granular lymphocytes. J Immunol 1991; 146: 1380–1384.

    PubMed  CAS  Google Scholar 

  666. Snapper CM, Paul WE. Interferon y and B cell stimulatory factor I reciprocally regulate Ig isotope production Science 1987; 236: 944–947.

    PubMed  CAS  Google Scholar 

  667. Snapper CM, Finkelman FD, and Paul WE. Differential regulation of IgGl and IgE synthesis by interleukin 4. J Exp Med 1988; 167: 183.

    PubMed  CAS  Google Scholar 

  668. Sondel PM, Hank JA, Kohler PC, et al. Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol 1986; 137: 502.

    PubMed  CAS  Google Scholar 

  669. Sondel PM, Sosman JA, Hank JA, et al. Tumor-infiltrating lymphocytes and interleukin-2 in melanomas (letter). N Engl J Med 1989; 320: 1418.

    PubMed  CAS  Google Scholar 

  670. Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988; 80: 1451.

    PubMed  CAS  Google Scholar 

  671. Southern E. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98: 503.

    PubMed  CAS  Google Scholar 

  672. Sower LE, Froelich CJ, Carney DH, et al. Thrombin induces IL-6 production in Fibroblasts and Epithelial Cells. J Immunol 1995; 155: 895–901.

    PubMed  CAS  Google Scholar 

  673. Squadrelli M, Rivoltini F, Gambacorti-Passerini C, et al. Pilot study of lymphokine activated killer cells and recombinant interleukin-2 in the local treatment of advanced head and neck cancers (meeting abstract). Sixth NCI/EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, A192,1989.

    Google Scholar 

  674. Spits H, Yssel H, Paliard X, et al. IL-4 inhibits IL-2 mediated induction of human lymphokine activated killer cells but not the generation of antigen specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 1988; 141:29–36.

    PubMed  CAS  Google Scholar 

  675. Splawski JB, Jelinek DF, Lipsky PE. Immunomodulatory role of IL-4 on the secretion of Ig by human B cells. J Immunol 1989; 142: 1569.

    PubMed  CAS  Google Scholar 

  676. Splawski JB, McAnally , Lipsky PE. IL2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2). J Immunol 1990; 144: 562.

    PubMed  CAS  Google Scholar 

  677. Stahel RA, Sculier JP, Jost LM, et al. Tolerance and effectiveness of recombinant interleukin-2 and lymphokine- activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol 1989; 25: 965.

    PubMed  CAS  Google Scholar 

  678. Standiford T, Kunkel S, Basha M, et al. Interleukin 8 gene expression by a pulmonary epithelial cell line. J Clin Invest 1990; 86: 1945.

    PubMed  CAS  Google Scholar 

  679. Starnes HF, Hartman G, Torti F, et al. Recombinant human interleukin-ip (IL-lp) has antitumor activity and acceptable toxicity in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1991; 10: 292.

    Google Scholar 

  680. Steller EP, Ottow RT, Eggermont AMM, et al. Local conditions in the host influence immunotherapy with interleukin- 2 and LAK cells. Cancer Det Prev 1988; 12: 81.

    CAS  Google Scholar 

  681. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphocyte cells. Proc Nat Acad Sci USA 1990; 87: 6808–6812.

    PubMed  CAS  Google Scholar 

  682. Stoter G, Shiloni E, Gundersen S, et al. Alternating recombinant interleukin-2 and dacarbazine in metastatic melanoma (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A1095.

    Google Scholar 

  683. Stoter G, Shiloni E, Aamdal S, et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study. Eur J Cancer Clin Oncol 1989; 25: S41–S43.

    PubMed  Google Scholar 

  684. Stotter H, Custer MC, Bolton ES, et al. IL7 induced lymphokine activated killer cell activity and is regulated by IL4. J Immunol 1991; 146: 150–155.

    PubMed  CAS  Google Scholar 

  685. Strassman G, Jacob CO, Fong M, Bertolini DR. Mechanisms of paraneoplastic syndromes of colon-26: involvement of interleukin 6 in hypercalcemia. Cytokine 1993;5:463–468.

    Google Scholar 

  686. Strassman G. Fong M, Freter CE, et al. Suramin interferes with Interleukin-6 receptor binding in vitro and inhibits colon 26 mediated experimental cachexia in vivo. J Clin Invest 1993; 92: 2152–2159.

    Google Scholar 

  687. Strieter R, Kunkel S, Showell H, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF alpha, LPS, and IL-1 Beta. Science 1989; 243: 1467.

    PubMed  CAS  Google Scholar 

  688. Streiter RM, Kunkel SL, Elner VM, et al. Interleukin-8: a corneal factor that induces neovascularization. Am J Pathol 1992; 141: 1279–1284.

    Google Scholar 

  689. Strohmeyer T, Peter S, Hartman M, et al. Expression of the hst-1 and c-kit protooncogene in human testicular germ cell tumors. Cancer Res 1991; 51: 181–1816.

    Google Scholar 

  690. Stutman O, Paige CJ, Figarella EF. Natural cytotoxic cells against solid tumors in mice. I. Strain and age distribution and target cell susceptibility. J Immunol 1979; 121: 1819.

    Google Scholar 

  691. Suda T, Murray R, Fischer M, et al. Tumor necrosis factor alpha and P40 induce day 15 murine fetal thymocyte proliferation in combination with IL-2. J Immunol 1990; 144:1783–1787.

    PubMed  CAS  Google Scholar 

  692. Sugarman BJ, Aggarwal BB, Hass PE, et al. Recombinant human tumor necrosis factor a: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230: 943–945.

    PubMed  CAS  Google Scholar 

  693. Swain SL, McKenzie DT, Dutton RW, et al. The role of IL- 2 and IL-5: characterization of a distinct helper T cell subset that makes IL4 and IL5 (Th2) and requires priming before induction of lymphokine secretion. Immunol Rev 1988; 102:77–106.

    PubMed  CAS  Google Scholar 

  694. Swain SL, McKenzie DT, Weinberg AD, Hancock W. Characterization of T helper 1 and 2 cell subsets in normal mice: helper T cells responsible for IL-4 and IL-5 production are present as precursors that require priming before they develop into lymphokine secreting cells. J Immunol 1994; 141:3445.

    Google Scholar 

  695. Symons JA, Young PR, Duff GW. Proc Natl Acad Sci USA 1995;92: 1714.

    PubMed  CAS  Google Scholar 

  696. Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992; 148: 1143–1148.

    PubMed  CAS  Google Scholar 

  697. Taga T, Hibi M, Yamasaki K, et al. Interleukin 6 triggers the association of its receptor with a possible signal transducer gp 130. Cell 1989; 58: 573–581.

    PubMed  CAS  Google Scholar 

  698. Takahashi GW, Andrews DF, Lilly MB, et al. Effect of granulocyte macrophage colony stimulating factor and interleukin 3 on interleukin 8 production by human neutrophils and monocytes. Blood 1993; 81: 357.

    PubMed  CAS  Google Scholar 

  699. Takatsu T. Interleukin 5 and its receptor. Prog Growth Factor Res 1991; 3: 87.

    PubMed  CAS  Google Scholar 

  700. Takenawa J, Kaneko Y, Fukumoto M. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Nat Cancer Inst 1991; 83: 1668–1672.

    PubMed  CAS  Google Scholar 

  701. Tanaguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned small cDNA for human interleukin-2. Nature 1983; 302: 305.

    Google Scholar 

  702. Tartaglia LA, Weber RF, Figari IS, et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Nat Acad Sci USA 1991; 88: 9292.

    PubMed  CAS  Google Scholar 

  703. Tartaglia LA, Pennica D, Goeddel DV Ligand passing: the 75 kDa tumor necrosis factor (TNF) receptor recruits TNF for signalling by the 55-kDa TNF receptor. J Biol Chem 1993; 268:18542–18548.

    PubMed  CAS  Google Scholar 

  704. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Brit J Cancer 1994; 69:911–913.

    PubMed  CAS  Google Scholar 

  705. Tavernier J, Devos R, Cornelius S, et al. A human high affinity interleukin-5 receptor (IL-5R) is composed of an IL5 specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell 1991; 66: 1175.

    PubMed  CAS  Google Scholar 

  706. Taylor CW, Grogan TM, Salmon SE. Effects of interleukin- 4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 1990; 75: 1114–1118.

    PubMed  CAS  Google Scholar 

  707. Tepper RI, Pattengale PK, Leder P. Murine interleukin 4 displays potent antitumor activity in vivo. Cell 1989; 57: 503–512.

    PubMed  CAS  Google Scholar 

  708. Tepper RI, Levinson DA, Stranger BZ, et al. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 1991; 62: 457–467.

    Google Scholar 

  709. TeVelde AA, Klomp JPG, Yard BA, et al. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immunol 1988; 140: 1548–1554.

    Google Scholar 

  710. Thijs LG, Hack CE, Strack van Schijndel RJM, et al. Complement activation and high-dose of interleukin-2 (letter). Lancet 1989; ii: 395.

    Google Scholar 

  711. Thompson JA, Lee DJ, Lindgren CG, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6: 669.

    PubMed  CAS  Google Scholar 

  712. Thompson JA, Peace DJ, Klarnet JP, et al. Eradication of disseminated murine leukemia by treatment with highdose interleukin 2. J Immunol 1986; 137: 3675.

    PubMed  CAS  Google Scholar 

  713. Thompsen MK, Larsen CG, Thompsen HK, et al. Recombinant human interleukin 8 is a potent activator of canine neutrophil aggregation migration and leukotrieneB4 biosynthesis. J Invest Dermatol 1991; 96: 260.

    Google Scholar 

  714. Thompson-Snipes LA, Dahr V, Bond MW, et al. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991; 173: 507–510.

    PubMed  CAS  Google Scholar 

  715. Thurman GB, Maluish AE, Rossio JL, et al. Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations. J Biol Response Modif 1986; 5:85.

    CAS  Google Scholar 

  716. Tilden AB, Itoh K, Blach CM. Human lymphokineactivated killer (LAK) cells: identification of two types of effector cells. J Immunol 1987; 138: 1068.

    PubMed  CAS  Google Scholar 

  717. Todaro GJ. Properties of growth factors produced by sarcoma virus-transformed cells. In: Moore N, ed. Progress in cancer research and therapy. Vol. 23: Maturation factors and cancer. Raven Press, New York, 1982: 115–128.

    Google Scholar 

  718. Toi M, Harris AL, Bicknell R. Interleukin 4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun 1991; 174: 1287–1293.

    PubMed  CAS  Google Scholar 

  719. Toi M, Bicknel R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992; 52:275–279.

    PubMed  CAS  Google Scholar 

  720. Toksoz D, Williams D, Smith KA, et al. Expression of two distinct DNA’s of the steel gene (SCF) in deficient murine stromal cell lines. Exp Hematol 1992; 20: 138–139.

    Google Scholar 

  721. Toksoz D, Zsebo KM, Smith KA, et al. Support of human hematopoiesis in the long term bone marrow cultures by murine stromal cells selectively expressing the membrane bound and secreted forms of the human analog of the steel gene product stem cell factor. Proc Nat Acad Sci USA 1992;89:7350–7354.

    PubMed  CAS  Google Scholar 

  722. Topalian SL, Solomon D, Rosenberg SA. Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989; 142: 3714–3725.

    PubMed  CAS  Google Scholar 

  723. Topalian SL, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988; 6: 839.

    PubMed  CAS  Google Scholar 

  724. Topp MS, Koenigsmann M, Mire-Sluis A, et al. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood 1993;82:2837–2844.

    PubMed  CAS  Google Scholar 

  725. Topp MS, Papadimitriou CA, Eitelbach F, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 1995; 55: 2173–2176.

    PubMed  CAS  Google Scholar 

  726. Tosato G, Pike SE. Interferon p2/interleukin-6 is a costimulant for human T lymphocytes. J Immunol 1988; 141: 1556–62.

    PubMed  CAS  Google Scholar 

  727. Touw I, vanAgthoven T, vanGurp R, et al. Interleukin 7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990; 75: 2097–2101.

    PubMed  CAS  Google Scholar 

  728. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470.

    PubMed  CAS  Google Scholar 

  729. Trehu EG, Isner JM, Mier JW, et al. Possible myocardial toxicity associated with interleukin 4 Therapy. J Immunotherapy 1993; 14: 348–351.

    CAS  Google Scholar 

  730. Treisman J, Higuchi CM, Thompson JA, et al. Enhancement by interleukin 4 of interleukin 2 or antibody induced proliferation of lymphocytes from interleukin 2 treated cancer patients. Cancer Res 1990; 50: 1160.

    PubMed  CAS  Google Scholar 

  731. Trinchieri G, Santoli D. Antiviral activity induced by culturing lymphocytes with tumor derived or virus transformed cells. Enhancement of natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 1978; 147: 1314.

    PubMed  CAS  Google Scholar 

  732. Trinchieri G, Matsumoto Kobayashi M, et al. Response of peripheral blood resting natural killer cells to interleukin- 2. J Exp Med 1984; 160: 1147.

    PubMed  CAS  Google Scholar 

  733. Triozzi P, Martin E, Kim J, et al. Phase lb trial of interleukin-ip (ILlβ)/interleukin-2 (IL2) in patients with metastatic cancer. Proc Am Soc Clin Oncol 1993; 12: 290.

    Google Scholar 

  734. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor αc are costimulators of interferon y production by in severe combined immunodeficiency mice with listeriosis and interleukin 10 is a physiologic antagonist. Proc Nat Acad Sci USA 1993; 90: 3725–3729.

    PubMed  CAS  Google Scholar 

  735. Tsuji K, Nakahata T, Takagi M et al. Effects of interleukin 3 and interleukin 4 on the development of ’connective tissue type’ mast cells: interleukin 3 supports their survival and interleukin 4 triggers and supports their proliferation synergistically with interleukin 3. Blood 1990; 75:421–427.

    PubMed  CAS  Google Scholar 

  736. Tsukuda M, Mochimatsu I, Sakumodo M, et al. Synergistic effects of Interleukin 2 and interleukin 7 on the proliferation and autologous tumor cell lysis of tumor associated lymphocytes. Biotherapy 1993; 6: 167–174.

    PubMed  CAS  Google Scholar 

  737. Tsunoda T, Tanimura H, Yamaue H, et al. The promotive effect of interleukin-4 with interleukin-2 in the proliferation of tumor infiltrating lymphocytes from patients with malignant tumor. Biotherapy 1992; 4: 9–15.

    PubMed  CAS  Google Scholar 

  738. Urba WJ, Clark JW, Steis RG, et al. Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations. J Natl Cancer Inst 1989; 81: 602.

    PubMed  CAS  Google Scholar 

  739. Usui N, Mimnaugh EG, Sinha BK. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin l a and etoposide against human melanoma cells. Cancer Res 1991; 51:769–774

    PubMed  CAS  Google Scholar 

  740. Uyttenhove C, Simpson R, VanSnick J. Functional and structural characterization of P40, a mouse glycoprotein with T cell growth factor activity. Proc Nat Acad Sci USA. 1988;85:6934–6939.

    PubMed  CAS  Google Scholar 

  741. Vaccarello L, Wang YL and Whiteside TL. Sustained outgrowth of auto tumor reactive T lymphocytes from human ovarian carcinomas in the presence of tumor necrosis factor a and interleukin 2. Human Immunology 1990;28:216–227.

    PubMed  CAS  Google Scholar 

  742. Valent P, Bevec D, Mauer D et al. Interleukin 4 promotes expression of mast cell ICAM-1 antigen. Proc Nat Acad Sci USA 1991;88:3339–3342.

    PubMed  CAS  Google Scholar 

  743. Valone FH, Gandara DR, Deisseroth A, et al. Interleukin- 2 (IL-2) combined with high-dose cisplatin (HDCP) and 5-fluorouracil (5-FU) in metastatic non-small cell lung (NSCLC) and head and neck cancer (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A755.

    Google Scholar 

  744. Van De Griend RJ, Krimpen BA, Ranfeltap CPM and Bolhuis RH. Rapidly expanded natural killer cell clones have strong antitumor cell activity and have surface phenotype of either T, non-T, or null cells. J Immunol 1984; 132:3185.

    PubMed  Google Scholar 

  745. Van derMeer JWM, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci (USA) 1988; 85: 1620–1623.

    Google Scholar 

  746. VanGameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human Interleukin-6 in cancer patients: a phase I-II trial. Blood 1994; 84: 1431–1441.

    Google Scholar 

  747. VanSnick J. Interleukin 6: an overview. Ann Rev Immunol 1990;8:253–280.

    Google Scholar 

  748. VanSnick J, Goethals A, Renauld J-C, et al. Cloning and characterization of cDNA for a new mouse T cell growth factor (P40) J Exp Med 1989; 169: 363–368.

    PubMed  Google Scholar 

  749. Viera P, deWaal Malefyt R, Dang M-N, et al. Isolation and expression of human cytokine synthesis inhibitory factor (CSIF/IL-10) cDNA clones: homology to Epstein Barr virus open reading frame BCRFI. Proc Nat Acad Sci USA 1991; 88: 1172–1176.

    Google Scholar 

  750. Vissinga CS, Fatur-Saunders DJ and Takei F. Dual role of IL-7 in the growth and differentiation of immature thymocytes. Experimental Hematology 1992; 20: 998–1003.

    PubMed  CAS  Google Scholar 

  751. Vitetta ES, Ohara J, Myers CD, et al. Serological biochemical and functional identity of B cell stimulatory factor-1 and B cell differentiation factor for IgGl. J Exp Med 1985; 162: 1726–1731.

    PubMed  CAS  Google Scholar 

  752. Vlasveld LT, Rankin EM, Hekman A, et al. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: clinical aspects. Br J Cancer 1992; 65: 744–750.

    PubMed  CAS  Google Scholar 

  753. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993; 11:1809–1816.

    PubMed  CAS  Google Scholar 

  754. VonFreeden-Jeffrey U, Viera P, Lucian LA, et al. Lymphopenia in interleukin (IL)-7 gene deleted mice identifies IL-7 and a nonredundant cytokine. J Exp Med 1995; 181: 1519–26.

    Google Scholar 

  755. Voss SD, Hong R, Sondel PM. Severe Combined Immunodeficiency, Interleukin 2 and the IL-2 receptor: experiments in nature continue to point the way. Blood 1194; 83:626–635.

    Google Scholar 

  756. Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil activating factor produced by monocytes. Biochem Biophys Res Commun 1987; 149: 755.

    PubMed  CAS  Google Scholar 

  757. Wang AM, Creasey AA, Ladner MD, et al. Molecular cloning of the complimentary DNA for human tumor necrosis factor. Science 1985; 228: 149.

    PubMed  CAS  Google Scholar 

  758. Wang YL, Lusheng S, Kanbaul A, et al. Lymphocytes infiltrating human ovarian tumors: Synergy between tumor necrosis factor a and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res 1989; 49: 5979–5985.

    PubMed  CAS  Google Scholar 

  759. Warren HS, Kinnear BF, Phillips JH, Lanier LL. Production of IL-5 by Human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12 .J Immunol 1995; 154:5144–5152.

    PubMed  CAS  Google Scholar 

  760. Warren RS, Starnes HF Jr, Gabrilove JL, et al. The acute metabolic effects of tumor necrosis factor administration in human. Arch Surg 1987; 122: 1396.

    PubMed  CAS  Google Scholar 

  761. Warringa RAJ, Koenderman L, Kok PTM, et al. Modulation and induction of eosinophil chemotaxis by granulocyte macrophage colony stimulating factor and interleukin 3. Blood 1991; 77: 2694.

    PubMed  CAS  Google Scholar 

  762. Watanabe Y, Kuribayashi K, Miatake S, et al. Exogenous expression of mouse interferon-y cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc Natl Acad Sci USA 1989; 86:9456–9460.

    PubMed  CAS  Google Scholar 

  763. Waterfield MD, Scarce T, Whittle N, et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28SIS of simian sarcoma virus. Nature 1983; 304: 34.

    Google Scholar 

  764. Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin 6 in patients with advanced cancer. J Clin Oncol 1993; 11: 499–506.

    PubMed  CAS  Google Scholar 

  765. Wei SJ, Liu JH, Blanchard DK, Djeu JY. Induction of IL8 gene expression in polymorphonuclear leukocytes by recombinant IL-2. J Immunol 1994; 142: 244.

    Google Scholar 

  766. Weil-Hillman G, Fisch P, Prieve AF, et al. Lymphokineactivated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and Leu 19 antigens but negative expression of CD 16 antigens. Cancer Res 1989; 49: 3680.

    PubMed  CAS  Google Scholar 

  767. Weiner L, Krigel R, Padavic K, et al. Potentiation of interleukin 2 effects by gamma-interferon in a Phase I clinical trial (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1989; 8: A723.

    Google Scholar 

  768. Weiss GR, Margolin KA, Sznol M, et al. Phase II study of the continuous infusion of Interleukin 6 for metastatic renal cell carcinoma. J Immunother 1995; 18: 52–56.

    CAS  Google Scholar 

  769. Welch PA, Namen AE, Goodwin RG, et al. Human IL-7: a novel T cell growth factor. J Immunol 1989; 143(11) 3562–3567.

    PubMed  CAS  Google Scholar 

  770. Weller PF, Rand TH, Barrett T, et al. Accessory cell function of eosinophils: HLA DR dependent MHC restricted antigen presentation and interleukin la formation. J Immunol 1993; 150: 2554.

    PubMed  CAS  Google Scholar 

  771. Welsh RM, Karre K, Hansson M, et al. Interferon mediated protection of normal and tumor target cells against lysis by mouse natural killer cells. J Immunol 1981;126:219–225.

    PubMed  CAS  Google Scholar 

  772. Welte K, Chang YW, Mertelsmann R, et al. Purification of human interleukin-2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 1982; 156: 435.

    Google Scholar 

  773. West WH, Tauer KW, Yannelli JR, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898.

    PubMed  CAS  Google Scholar 

  774. Widmer M. Grabstein K. Regulation of cytolytic Tlymphocyte generation by B cell stimulatory factor 1. Nature 1987; 326: 795–798.

    PubMed  CAS  Google Scholar 

  775. Widmer M. Acres R, Sassenfeld H, Grabstein K. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J Exp Med 1987; 166: 1447.

    PubMed  CAS  Google Scholar 

  776. Widmer MB, Morrissey PJ, Namen AE, et al. Interleukin 7 stimulates the growth of fetal thymic precursors of cytolytic cells: induction of effector function by interleukin 2 and inhibition by interleukin 4. Int Immunol 1990; 2: 1055–1061.

    PubMed  CAS  Google Scholar 

  777. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit proto-oncogene Cell 1990; 63: 167–174.

    PubMed  CAS  Google Scholar 

  778. Williams DE, Morrissey PJ, Mochizuki DY, et al. T cell growth factor P40 promotes the proliferation of myeloid cell lines and enhances erythroid burst formation by normal murine bone marrow cells in vitro. Blood 1990; 76:906–911.

    PubMed  CAS  Google Scholar 

  779. Williams N, Eger RR, Jackson HN, et al. Two factor requirement for murine megakaryocyte colony formation. J Cell Physiol 1982; 110: 101.

    PubMed  CAS  Google Scholar 

  780. Williamson BD, Carswell EA, Rubin BY, et al. Human tumor necrosis factor produced by human B cell lines. Synergistic cytotoxic interaction with human interferon y. Proc Nat Acad Sci USA 1983; 80: 5397–5401.

    PubMed  CAS  Google Scholar 

  781. Wilson AB, Harris JM, Coomb RRA. Interleukin 2 induction of interferon gamma by resting human T cells and large granular lymphocytes: requirement for accessory factors including interleukin-1. Cellular Immunology 1988; 113: 130.

    PubMed  CAS  Google Scholar 

  782. Witmer-Pack MD, Olivier W, Valinsky J, et al. Granulocyte/ macrophage colony stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J Exp Med 1987; 166: 1484.

    PubMed  CAS  Google Scholar 

  783. Wolf SF, Sieburth D, Sypek J. Interleukin 12: A key modulator of immune response. Stem Cells 1994; 12:154–168.

    PubMed  CAS  Google Scholar 

  784. Wolf SF, Temple PA, Kobayashi M, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146: 3074–3081.

    PubMed  CAS  Google Scholar 

  785. Wright SD, Ramos RA, Tobias PS, et al. CD 14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431.

    PubMed  CAS  Google Scholar 

  786. Wu C, Demeure C, Kiniwa M, et al. IL-12 induces production of IFN-y by neonatal human CD4 T cells. J Immunol 1993; 151: 1938–1949.

    PubMed  CAS  Google Scholar 

  787. Wu S, Boyer CM, Whittaker RS, et al. Tumor necrosis factor as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumor cell proliferation and tumor necrosis factor alpha production. Cancer Res 1993; 53: 1939.

    PubMed  CAS  Google Scholar 

  788. Yaden Y, Kuang WS, Yang-Feng T, et al. Human protooncogene C kit, a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 3341–3351.

    Google Scholar 

  789. Yang YC, Riccaciardi S, Ciarletta A, et al. Expression cloning of a cDNA encoding a novel human hematopoietic growth factor: Human homologue of murine T cell growth factor P40. Blood 1989; 74: 1880–1884.

    PubMed  CAS  Google Scholar 

  790. Yamagushi Y, Suda T, Suda J, et al. Purified Interleukin 5 supports the terminal differentiation and proliferation of purified eosinophil precursors. J Exp Med 1988; 167: 43.

    Google Scholar 

  791. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin 6 (BSF-2/IFN beta 2) receptor. Science 1988; 241: 825–828.

    PubMed  CAS  Google Scholar 

  792. Yasamura S, Lin WC, Weidemann E, et al. Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin-2. Int J Cancer 1994; 59: 225–234.

    Google Scholar 

  793. Yasumoto K, Miyazaki K, Nagashima A, et al. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987; 47:2184.

    PubMed  CAS  Google Scholar 

  794. Yokota T, Arai N, DeVries et al. Molecular biology of interleukin 4 and interleukin 5 genes and biology of their products that stimulate B cells, T cells and hematopoietic cells. Immunol Rev 1988; 102: 137–187.

    PubMed  CAS  Google Scholar 

  795. Yokota T, Coffman RL, Hagiwara H, et al. Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor eosinophil colony-stimulating activities: relationship to interleukin 5. Proc Natl Sci (USA) 1987; 84: 7388–7392.

    CAS  Google Scholar 

  796. Yousefi S, Hemmann S, Weber M, et al. IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma. J Immunol 1995; 154: 5481–5490.

    PubMed  CAS  Google Scholar 

  797. Yssel H, Schneider PV, Lanier LL. Interleukin 7 specifically induces the B7/BB1 antigen on human cord blood and peripheral blood T cells and T cell clones. Int Immunol 1993; 5: 753–759.

    PubMed  CAS  Google Scholar 

  798. Yu JS, Wei MX, Chjiocca A, et al. Treatment of glioma with engineered interleukin 4 secreting cells. Cancer Res 1993;53:3125–3128.

    PubMed  CAS  Google Scholar 

  799. Zhang JZ, Maruyama K, Iwatsuki K, Kaneko F. Regulatory effects of 1, 25-dihydroxyvitamin D3 and a novel Vitamin D3 analog MC903 on secretion of interleukin 1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line(HSC-1).J Dermatological Sci 1994; 7: 24–31.

    CAS  Google Scholar 

  800. Zhou A, Hassel BA, Silverman RH. Expression cloning of 2-5A-dependent RNAase: A uniquely regulated mediator of interferon action. Cell 1993; 72: 753–765.

    PubMed  CAS  Google Scholar 

  801. Zimmerman RJ, Aukerman SL, Young JD, et al. Schedule dependency of antitumor activity and toxicity of polyethylene glycol-modified IL-2 murine tumors (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1989; 30: A1435.

    Google Scholar 

  802. Zitrogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with ILl2. Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393–1403.

    Google Scholar 

  803. Zoltnik A, Fisher M, Roehm N, and Zipori D. Evidence for effects of (B cell stimulatory factor 1) on macrophages: enhancement of antigen presenting ability of bone marrow derived macrophages. J Immunol 1987; 138:4275.

    Google Scholar 

  804. Zoltnick A, Ransom J, Frank G, et al. Interleukin 4 is a growth factor for activated thymocytes: possible role in T cell ontogeny Proc Nat Acad Sci USA 1987; 84: 3856.

    Google Scholar 

  805. Zsebo KM, Wypych J, McNiece IK, et al. Identification characterization and biological characterization of hematopoietic stem cell factor form Buffalo rat liver conditioned medium. Cell 1990; 63: 195–210.

    PubMed  CAS  Google Scholar 

  806. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990; 63: 312–224.

    Google Scholar 

  807. Zubiaga AM, Munoz E, Huber BT. IL-2 and IL-4 selectively rescue Th cell subsets from glucocorticoid induced apoptosis. J Immunol 1992; 149: 107–112.

    PubMed  CAS  Google Scholar 

  808. Zukiwski AA, Itoh K, Benjamin R, et al. Pilot study of rIL-2 administered with a murine anti-melanoma antibody in patients with metastatic melanoma (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1989; 30: A1448.

    Google Scholar 

  809. Zurawski G, deVries JE. Interleukin 13, an interleukin 4 like cytokine that acts on monocytes and B cells but not T cells. Immunol Today 1994; 15: 19–29.

    PubMed  CAS  Google Scholar 

  810. Zurawski G, deVries JE. Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cells 1994; 12: 169–174.

    PubMed  CAS  Google Scholar 

  811. Zurawski SM, Vega F, Huyghe B, Zurawski G. Receptors for interleukin 13 and interleukin 4 are complex and share a novel component that functions in signal transduction. EMBO 1993; 12: 3899–3905.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Synertron, Inc., Madison, Wisconsin, USA

    Walter Lewko

  2. Biological Therapy Institute Foundation, Franklin, Tennessee, USA

    Richard V. Smalley

  3. University of Missouri, Columbia, Missouri, USA

    Robert K. Oldham & Robert K. Oldham

Authors
  1. Walter Lewko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard V. Smalley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert K. Oldham
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biological Therapy Institute Foundation, Franklin, Tennessee, USA

    Robert K. Oldham M.D. (Clinical Professor of Medicine) (Clinical Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lewko, W., Smalley, R.V., Oldham, R.K. (1998). Lymphokines and Cytokines. In: Oldham, R.K. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0029-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0029-5_10

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6501-6

  • Online ISBN: 978-94-009-0029-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation